Design	O
and	O
use	O
of	O
an	O
inducibly	O
activated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	B-protein
to	O
study	O
immune	O
modulation	O
.	O

The	O
Nef	B-protein
protein	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
infectivity	O
of	O
virus	O
particles	O
,	O
downmodulate	O
cell	B-protein
surface	I-protein
proteins	I-protein
,	O
and	O
associate	O
with	O
many	O
intracellular	B-protein
proteins	I-protein
that	O
are	O
thought	O
to	O
facilitate	O
HIV	O
infection	O
.	O

One	O
of	O
the	O
challenges	O
in	O
defining	O
the	O
molecular	O
events	O
regulated	O
by	O
Nef	B-protein
has	O
been	O
obtaining	O
good	O
expression	O
of	O
Nef	B-protein
protein	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
has	O
been	O
attributed	O
to	O
effects	O
of	O
Nef	B-protein
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

We	O
have	O
designed	O
a	O
Nef	B-protein
protein	I-protein
that	O
is	O
readily	O
expressed	O
in	O
T-cell	B-cell_line
lines	I-cell_line
and	O
whose	O
function	O
is	O
inducibly	O
activated	O
.	O

It	O
is	O
composed	O
of	O
a	O
fusion	O
between	O
full-length	B-protein
Nef	I-protein
and	O
the	O
estrogen	B-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
(	O
Nef-ER	B-protein
)	O
.	O

The	O
Nef-ER	B-protein
is	O
kept	O
in	O
an	O
inactive	O
state	O
due	O
to	O
steric	O
hindrance	O
,	O
and	O
addition	O
of	O
the	O
membrane-permeable	O
drug	O
4-hydroxytamoxifen	O
(	O
4-HT	O
)	O
,	O
which	O
binds	O
to	O
the	O
ER	B-protein
domain	I-protein
,	O
leads	O
to	O
inducible	O
activation	O
of	O
Nef-ER	B-protein
within	O
cells	O
.	O

We	O
demonstrate	O
that	O
Nef-ER	B-protein
inducibly	O
associates	O
with	O
the	O
62-kDa	B-protein
Ser/Thr	I-protein
kinase	I-protein
and	O
is	O
localized	O
to	O
specific	O
membrane	O
microdomains	O
(	O
lipid	O
rafts	O
)	O
only	O
after	O
activation	O
.	O

Using	O
this	O
inducible	O
Nef	B-protein
,	O
we	O
also	O
compared	O
the	O
specific	O
requirements	O
for	O
CD4	B-protein
and	O
HLA-A2	B-protein
downmodulation	O
in	O
a	O
SupT1	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Half-maximal	O
downmodulation	O
of	O
cell	B-protein
surface	I-protein
CD4	I-protein
required	O
very	O
little	O
active	O
Nef-ER	B-protein
and	O
occurred	O
as	O
early	O
as	O
4	O
h	O
after	O
addition	O
of	O
4-HT	O
.	O

In	O
contrast	O
,	O
50	O
%	O
downmodulation	O
of	O
HLA-A2	B-protein
by	O
Nef	B-protein
required	O
16	O
to	O
24	O
h	O
and	O
about	O
50-	O
to	O
100-fold-greater	O
concentrations	O
of	O
4-HT	O
.	O

These	O
data	O
suggest	O
that	O
HLA-A2	B-protein
downmodulation	O
may	O
require	O
certain	O
threshold	O
levels	O
of	O
active	O
Nef	B-protein
.	O

The	O
differential	O
timing	O
of	O
CD4	B-protein
and	O
HLA-A2	B-protein
downmodulation	O
may	O
have	O
implications	O
for	O
HIV	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O

JOURNAL	NULL
or	NULL
ViROLOGY	NULL
,	NULL
Jan.	NULL
2001	NULL
,	NULL
p.	NULL
834-843	NULL
0022-538	NULL
X/01/	NULL
$	NULL
04.00+0	NULL
-	NULL
DOI	NULL
:	NULL
10.1128/JV1.75.2.834-843.2001	NULL
Vol	NULL
.	NULL

75	NULL
,	NULL
No	NULL
.	NULL

2	NULL
Copyright	NULL
©	NULL
2001	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Design	NULL
and	NULL
Use	NULL
of	NULL
an	NULL
Inducibly	NULL
Activated	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Nef	NULL
To	NULL
Study	NULL
Immune	NULL
Modulation	NULL
SCOTT	NULL
F.	NULL
WALK	NULL
,	NULL
MELISSA	NULL
ALEXANDER	NULL
,	NULL
BERNHARD	NULL
MAIER	NULL
,	NULL
MARIE-LOUISE	NULL
HAMMARSKJOLD	NULL
,	NULL
DAVID	NULL
M.	NULL
REKOSH	NULL
,	NULL
anp	NULL
KODI	NULL
S.	NULL
RAVICHANDRAN®*	NULL
Carter	NULL
Immunology	NULL
Center	NULL
,	NULL
Myles	NULL
H.	NULL
Thaler	NULL
Center	NULL
for	NULL
AIDS	NULL
and	NULL
Human	NULL
Retrovirus	NULL
Research	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Charlottesville	NULL
,	NULL
Virginia	NULL
22908	NULL
Received	NULL
30	NULL
June	NULL
2000/Accepted	NULL
25	NULL
October	NULL
2000	NULL
The	NULL
Nef	NULL
protein	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
the	NULL
infectivity	NULL
of	NULL
virus	NULL
particles	NULL
,	NULL
downmodulate	NULL
cell	NULL
surface	NULL
proteins	NULL
,	NULL
and	NULL
associate	NULL
with	NULL
many	NULL
intracellular	NULL
proteins	NULL
that	NULL
are	NULL
thought	NULL
to	NULL
facilitate	NULL
HIV	NULL
infection	NULL
.	NULL

One	NULL
of	NULL
the	NULL
challenges	NULL
in	NULL
defining	NULL
the	NULL
molecular	NULL
events	NULL
regulated	NULL
by	NULL
Nef	NULL
has	NULL
been	NULL
obtaining	NULL
good	NULL
expression	NULL
of	NULL
Nef	NULL
protein	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
effects	NULL
of	NULL
Nef	NULL
on	NULL
cell	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
.	NULL

We	NULL
have	NULL
designed	NULL
a	NULL
Nef	NULL
protein	NULL
that	NULL
is	NULL
readily	NULL
expressed	NULL
in	NULL
T-cell	NULL
lines	NULL
and	NULL
whose	NULL
function	NULL
is	NULL
inducibly	NULL
activated	NULL
.	NULL

It	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
fusion	NULL
between	NULL
full-length	NULL
Nef	NULL
and	NULL
the	NULL
estrogen	NULL
receptor	NULL
hormone-binding	NULL
domain	NULL
(	NULL
Nef-ER	NULL
)	NULL
.	NULL

The	NULL
Nef-ER	NULL
is	NULL
kept	NULL
in	NULL
an	NULL
inactive	NULL
state	NULL
due	NULL
to	NULL
steric	NULL
hindrance	NULL
,	NULL
and	NULL
addition	NULL
of	NULL
the	NULL
membrane-permeable	NULL
drug	NULL
4-hydroxytamoxifen	NULL
(	NULL
4-HT	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
ER	NULL
domain	NULL
,	NULL
leads	NULL
to	NULL
inducible	NULL
activation	NULL
of	NULL
Nef-ER	NULL
within	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
Nef-ER	NULL
inducibly	NULL
associates	NULL
with	NULL
the	NULL
62-kDa	NULL
Ser/Thr	NULL
kinase	NULL
and	NULL
is	NULL
localized	NULL
to	NULL
specific	NULL
membrane	NULL
microdomains	NULL
(	NULL
lipid	NULL
rafts	NULL
)	NULL
only	NULL
after	NULL
activation	NULL
.	NULL

Using	NULL
this	NULL
inducible	NULL
Nef	NULL
,	NULL
we	NULL
also	NULL
compared	NULL
the	NULL
specific	NULL
requirements	NULL
for	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
in	NULL
a	NULL
SupT1	NULL
T-cell	NULL
line	NULL
.	NULL

Half-maximal	NULL
downmodulation	NULL
of	NULL
cell	NULL
surface	NULL
CD4	NULL
required	NULL
very	NULL
little	NULL
active	NULL
Nef-ER	NULL
and	NULL
occurred	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
4-HT	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
50	NULL
%	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
by	NULL
Nef	NULL
required	NULL
16	NULL
to	NULL
24	NULL
h	NULL
and	NULL
about	NULL
50-	NULL
to	NULL
100-fold-greater	NULL
concentrations	NULL
of	NULL
4-HT	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
HLA-A2	NULL
downmodulation	NULL
may	NULL
require	NULL
certain	NULL
threshold	NULL
levels	NULL
of	NULL
active	NULL
Nef	NULL
.	NULL

The	NULL
differential	NULL
timing	NULL
of	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
may	NULL
have	NULL
implications	NULL
for	NULL
HIV	NULL
pathogenesis	NULL
and	NULL
immune	NULL
evasion	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
nef	NULL
gene	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV	NULL
(	NULL
42	NULL
,	NULL
48	NULL
,	NULL
53	NULL
)	NULL
.	NULL

While	NULL
not	NULL
essential	NULL
for	NULL
viral	NULL
replication	NULL
in	NULL
tissue	NULL
culture	NULL
cells	NULL
,	NULL
nef	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
maintenance	NULL
of	NULL
viral	NULL
load	NULL
and	NULL
progression	NULL
to	NULL
AIDS	NULL
in	NULL
rhesus	NULL
macaques	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
identification	NULL
of	NULL
deletions	NULL
within	NULL
the	NULL
nef	NULL
gene	NULL
in	NULL
individuals	NULL
who	NULL
have	NULL
remained	NULL
asymptomatic	NULL
for	NULL
a	NULL
number	NULL
of	NULL
years	NULL
suggests	NULL
an	NULL
important	NULL
role	NULL
for	NULL
Nef	NULL
in	NULL
HIV	NULL
pathogenesis	NULL
in	NULL
humans	NULL
(	NULL
15	NULL
,	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
transgenic	NULL
mice	NULL
expressing	NULL
Nef	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
develop	NULL
a	NULL
disease	NULL
that	NULL
mimics	NULL
pediatric	NULL
AIDS	NULL
(	NULL
21	NULL
)	NULL
.	NULL

HIV-1	NULL
(	NULL
NL4-3	NULL
)	NULL
nef	NULL
encodes	NULL
a	NULL
206-amino-acid	NULL
(	NULL
27-	NULL
to	NULL
34-kDa	NULL
)	NULL
myristoylated	NULL
Nef	NULL
protein	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Several	NULL
structural	NULL
features	NULL
of	NULL
Nef	NULL
have	NULL
been	NULL
recognized	NULL
.	NULL

Nef	NULL
contains	NULL
an	NULL
N-terminal	NULL
myristoylation	NULL
sequence	NULL
that	NULL
helps	NULL
to	NULL
localize	NULL
it	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
many	NULL
of	NULL
its	NULL
known	NULL
functions	NULL
(	NULL
22	NULL
,	NULL
26	NULL
,	NULL
67	NULL
)	NULL
.	NULL

Nef	NULL
also	NULL
contains	NULL
a	NULL
stretch	NULL
of	NULL
acidic	NULL
residues	NULL
,	NULL
several	NULL
PXXP	NULL
motifs	NULL
,	NULL
and	NULL
a	NULL
dileucine	NULL
motif	NULL
that	NULL
have	NULL
been	NULL
implicated	NULL
as	NULL
important	NULL
regions	NULL
for	NULL
Nef	NULL
function	NULL
(	NULL
1	NULL
,	NULL
42	NULL
,	NULL
45	NULL
,	NULL
48	NULL
,	NULL
55	NULL
,	NULL
56	NULL
,	NULL
62	NULL
)	NULL
.	NULL

Many	NULL
studies	NULL
on	NULL
the	NULL
role	NULL
of	NULL
Nef	NULL
in	NULL
HIV	NULL
infection	NULL
have	NULL
ascribed	NULL
numerous	NULL
potential	NULL
functions	NULL
for	NULL
Nef	NULL
.	NULL

The	NULL
ones	NULL
that	NULL
have	NULL
been	NULL
consistently	NULL
observed	NULL
are	NULL
(	NULL
i	NULL
)	NULL
the	NULL
greater	NULL
infectivity	NULL
of	NULL
Nef-containing	NULL
viruses	NULL
than	NULL
of	NULL
Nef-deleted	NULL
variants	NULL
(	NULL
2	NULL
,	NULL
11	NULL
,	NULL
43	NULL
,	NULL
60	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
downmodulation	NULL
of	NULL
CD4	NULL
molecules	NULL
from	NULL
the	NULL
surface	NULL
of	NULL
infected	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
17	NULL
,	NULL
20	NULL
,	NULL
41	NULL
)	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
downmodulation	NULL
of	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
antigen	NULL
HLA-A2	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Carter	NULL
Immunology	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Bldg	NULL
.	NULL

MR4	NULL
,	NULL
Rm	NULL
.	NULL

4012F	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
801386	NULL
,	NULL
HSC	NULL
,	NULL
Charlottesville	NULL
,	NULL
VA	NULL
22908-1386	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
804	NULL
)	NULL
243-6093	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
804	NULL
)	NULL
924-1221	NULL
.	NULL

E-mail	NULL
:	NULL
Ravi	NULL
@	NULL
virginia.edu	NULL
.	NULL

834	NULL
(	NULL
12	NULL
,	NULL
14	NULL
,	NULL
36	NULL
,	NULL
61	NULL
)	NULL
;	NULL
(	NULL
iv	NULL
)	NULL
activation	NULL
of	NULL
quiescent	NULL
T	NULL
cells	NULL
(	NULL
59	NULL
,	NULL
63	NULL
)	NULL
;	NULL
and	NULL
(	NULL
v	NULL
)	NULL
interaction	NULL
of	NULL
Nef	NULL
with	NULL
cellular	NULL
kinases	NULL
of	NULL
the	NULL
PAK	NULL
(	NULL
p21-activated	NULL
kinase	NULL
)	NULL
family	NULL
.	NULL

Although	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
PAK	NULL
associated	NULL
with	NULL
Nef	NULL
remains	NULL
uncertain	NULL
,	NULL
this	NULL
association	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
efficient	NULL
pathogenesis	NULL
(	NULL
6	NULL
,	NULL
16	NULL
,	NULL
44	NULL
,	NULL
52	NULL
,	NULL
58	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
is	NULL
controversial	NULL
since	NULL
other	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
interaction	NULL
of	NULL
Nef	NULL
with	NULL
PAK	NULL
is	NULL
not	NULL
a	NULL
prerequisite	NULL
for	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
to	NULL
achieve	NULL
a	NULL
high	NULL
viral	NULL
load	NULL
and	NULL
for	NULL
pathogenesis	NULL
(	NULL
8	NULL
,	NULL
33	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
above	NULL
,	NULL
Nef	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
associate	NULL
with	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
proteins	NULL
,	NULL
many	NULL
of	NULL
which	NULL
seem	NULL
to	NULL
be	NULL
unique	NULL
to	NULL
the	NULL
system	NULL
used	NULL
(	NULL
42	NULL
,	NULL
55	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
many	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
been	NULL
performed	NULL
in	NULL
cells	NULL
which	NULL
are	NULL
not	NULL
the	NULL
natural	NULL
hosts	NULL
for	NULL
HIV	NULL
infection	NULL
complicates	NULL
the	NULL
interpretation	NULL
of	NULL
these	NULL
results	NULL
and	NULL
may	NULL
,	NULL
in	NULL
part	NULL
,	NULL
explain	NULL
these	NULL
discrepancies	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
reported	NULL
difficulties	NULL
obtaining	NULL
high	NULL
expression	NULL
and	NULL
the	NULL
loss	NULL
of	NULL
expression	NULL
of	NULL
Nef	NULL
over	NULL
time	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

While	NULL
several	NULL
groups	NULL
have	NULL
transiently	NULL
expressed	NULL
Nef	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
or	NULL
T-cell	NULL
lines	NULL
using	NULL
retrovirus-mediated	NULL
gene	NULL
transfer	NULL
or	NULL
DNA	NULL
transfections	NULL
(	NULL
6	NULL
,	NULL
23	NULL
,	NULL
39	NULL
)	NULL
,	NULL
stable	NULL
high-level	NULL
expression	NULL
of	NULL
Nef	NULL
has	NULL
been	NULL
difficult	NULL
to	NULL
achieve	NULL
.	NULL

One	NULL
approach	NULL
that	NULL
has	NULL
been	NULL
used	NULL
is	NULL
the	NULL
generation	NULL
of	NULL
CD8-Nef	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
domains	NULL
of	NULL
CD8e	NULL
chain	NULL
fused	NULL
to	NULL
Nef	NULL
in	NULL
its	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Only	NULL
low	NULL
surface	NULL
expression	NULL
could	NULL
be	NULL
achieved	NULL
,	NULL
and	NULL
the	NULL
stable	NULL
clones	NULL
that	NULL
express	NULL
CD8-Nef	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
acquire	NULL
mutations	NULL
that	NULL
preclude	NULL
expression	NULL
of	NULL
CD8-Nef	NULL
.	NULL

While	NULL
this	NULL
CD8-Nef	NULL
construct	NULL
has	NULL
been	NULL
useful	NULL
in	NULL
delineating	NULL
certain	NULL
features	NULL
of	NULL
Nef	NULL
function	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
dimerization	NULL
of	NULL
Nef	NULL
(	NULL
since	NULL
CD8	NULL
is	NULL
normally	NULL
a	NULL
dimer	NULL
)	NULL
and	NULL
the	NULL
constitutive	NULL
presence	NULL
on	NULL
the	NULL
membrane	NULL
of	NULL
CD8-Nef	NULL
(	NULL
instead	NULL
of	NULL
the	NULL
myristoylation-dependent	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
localization	NULL
of	NULL
native	NULL
Nef	NULL
)	NULL
are	NULL
not	NULL
known	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
a	NULL
fraction	NULL
of	NULL
the	NULL
Nef	NULL
protein	NULL
is	NULL
contained	NULL
in	NULL
specific	NULL
membrane	NULL
microdomains	NULL
known	NULL
as	NULL
lipid	NULL
rafts	NULL
(	NULL
65	NULL
)	NULL
;	NULL
whether	NULL
CD8-Nef	NULL
localizes	NULL
to	NULL
similar	NULL
microdomains	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
Nef	NULL
function	NULL
,	NULL
we	NULL
attempted	NULL
to	NULL
design	NULL
a	NULL
regulatable	NULL
Nef	NULL
that	NULL
would	NULL
remain	NULL
basally	NULL
inactive	NULL
in	NULL
cells	NULL
and	NULL
whose	NULL
function	NULL
could	NULL
be	NULL
induced	NULL
when	NULL
desired	NULL
.	NULL

Toward	NULL
this	NULL
goal	NULL
,	NULL
we	NULL
engineered	NULL
a	NULL
Nef-ER	NULL
(	NULL
estrogen	NULL
receptor	NULL
)	NULL
fusion	NULL
protein	NULL
that	NULL
contains	NULL
Nef	NULL
fused	NULL
at	NULL
its	NULL
C	NULL
terminus	NULL
to	NULL
the	NULL
hormone-binding	NULL
domain	NULL
of	NULL
the	NULL
ER	NULL
.	NULL

It	NULL
has	NULL
been	NULL
previously	NULL
demonstrated	NULL
that	NULL
fusion	NULL
of	NULL
the	NULL
ER	NULL
to	NULL
kinases	NULL
such	NULL
as	NULL
Raf	NULL
and	NULL
Akt	NULL
leads	NULL
to	NULL
an	NULL
inactive	NULL
kinase	NULL
due	NULL
to	NULL
steric	NULL
hindrance	NULL
of	NULL
these	NULL
kinases	NULL
by	NULL
the	NULL
proteins	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
ER	NULL
domain	NULL
(	NULL
30	NULL
,	NULL
31	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Inducible	NULL
activation	NULL
can	NULL
be	NULL
achieved	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
drug	NULL
4-hydroxytamoxifen	NULL
(	NULL
4-HT	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
ER	NULL
and	NULL
relieves	NULL
the	NULL
inhibition	NULL
.	NULL

Since	NULL
several	NULL
different	NULL
regions	NULL
of	NULL
Nef	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
various	NULL
functions	NULL
ascribed	NULL
to	NULL
Nef	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
a	NULL
similar	NULL
fusion	NULL
of	NULL
ER	NULL
to	NULL
Nef	NULL
would	NULL
lead	NULL
to	NULL
inhibition	NULL
of	NULL
Nef	NULL
function	NULL
and	NULL
that	NULL
addition	NULL
of	NULL
4-HT	NULL
would	NULL
lead	NULL
to	NULL
its	NULL
inducible	NULL
activation	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
such	NULL
a	NULL
Nef-ER	NULL
protein	NULL
can	NULL
be	NULL
readily	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
that	NULL
4-HT	NULL
addition	NULL
leads	NULL
to	NULL
Nef-dependent	NULL
downmodulation	NULL
of	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Nef-ER	NULL
interaction	NULL
with	NULL
cellular	NULL
kinases	NULL
.	NULL

This	NULL
provides	NULL
a	NULL
novel	NULL
approach	NULL
to	NULL
delineate	NULL
Nef	NULL
function	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

SupT1	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
AIDS	NULL
repository	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
along	NULL
with	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
a	NULL
penicillin-strepto-mycin	NULL
,	NULL
and	NULL
20	NULL
M	NULL
2-mercaptocthanol	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

The	NULL
plasmid	NULL
encoding	NULL
Nef-ER	NULL
was	NULL
constructed	NULL
in	NULL
the	NULL
pEBB	NULL
vector	NULL
,	NULL
which	NULL
drives	NULL
expression	NULL
under	NULL
the	NULL
elongation	NULL
factor	NULL
1	NULL
«	NULL
(	NULL
EF-1	NULL
«	NULL
)	NULL
promoter	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
pBB	NULL
Nef-ER-IRES-puro	NULL
vector	NULL
,	NULL
which	NULL
expresses	NULL
Nef-ER	NULL
as	NULL
part	NULL
of	NULL
bicistronic	NULL
message	NULL
with	NULL
an	NULL
internal	NULL
ribosomal	NULL
entry	NULL
sequence	NULL
(	NULL
IRES	NULL
)	NULL
followed	NULL
by	NULL
the	NULL
coding	NULL
sequence	NULL
for	NULL
the	NULL
puromycin	NULL
resistance	NULL
gene	NULL
(	NULL
Puro	NULL
)	NULL
,	NULL
was	NULL
constructed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
following	NULL
linker	NULL
sequence	NULL
was	NULL
cloned	NULL
into	NULL
pBluescript	NULL
(	NULL
pBS	NULL
)	NULL
between	NULL
the	NULL
NofI	NULL
and	NULL
Xho	NULL
!	NULL

sites	NULL
:	NULL
GCGGCCGCCGGAGCAGGCAATTGGGAT	NULL
CCGTCGACCATATGCCATGGAGATCTAAGCTTACGCGTATCGATGC	NULL
GGCCGCCTCGAG	NULL
.	NULL

The	NULL
Puro	NULL
element	NULL
from	NULL
the	NULL
pBABEpuro	NULL
vector	NULL
was	NULL
excised	NULL
using	NULL
HindIII	NULL
and	NULL
Clel	NULL
sites	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
HindIM-Clel	NULL
sites	NULL
of	NULL
the	NULL
modified	NULL
pBS	NULL
.	NULL

The	NULL
murine	NULL
ER	NULL
coding	NULL
sequence	NULL
(	NULL
amino	NULL
acids	NULL
281	NULL
to	NULL
485	NULL
)	NULL
was	NULL
excised	NULL
from	NULL
plasmid	NULL
pWZL-Neo	NULL
Akt-ER	NULL
(	NULL
31	NULL
)	NULL
using	NULL
EcoRI	NULL
and	NULL
Se/l	NULL
fragments	NULL
and	NULL
cloned	NULL
into	NULL
the	NULL
MefT-Sa/l	NULL
sites	NULL
of	NULL
the	NULL
pBS-puro	NULL
vector	NULL
.	NULL

The	NULL
murine	NULL
ER	NULL
domain	NULL
has	NULL
a	NULL
point	NULL
mutation	NULL
engineered	NULL
to	NULL
prevent	NULL
the	NULL
binding	NULL
of	NULL
estrogen	NULL
but	NULL
allow	NULL
high-affinity	NULL
binding	NULL
to	NULL
the	NULL
estrogen	NULL
analogue	NULL
4-HT	NULL
.	NULL

The	NULL
IRES	NULL
was	NULL
excised	NULL
from	NULL
the	NULL
pMSCV-IRES-puro	NULL
vector	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Bill	NULL
Sha	NULL
,	NULL
Berkeley	NULL
,	NULL
Calif.	NULL
)	NULL
using	NULL
Se/l	NULL
and	NULL
Neo	NULL
!	NULL

and	NULL
subcloned	NULL
3	NULL
'	NULL
of	NULL
the	NULL
ER	NULL
coding	NULL
sequence	NULL
into	NULL
Sall-Ncol	NULL
sites	NULL
of	NULL
the	NULL
modified	NULL
pBS	NULL
.	NULL

A	NULL
PCR	NULL
product	NULL
encoding	NULL
full-length	NULL
HIV-1	NULL
(	NULL
NL4-3	NULL
)	NULL
Nef	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
pEBB	NULL
vector	NULL
as	NULL
a	NULL
BamHI-Clel	NULL
fragment	NULL
.	NULL

The	NULL
ER-IRES-Puro	NULL
segment	NULL
from	NULL
pBS	NULL
described	NULL
above	NULL
was	NULL
then	NULL
excised	NULL
as	NULL
a	NULL
Not	NULL
!	NULL

fragment	NULL
and	NULL
subcloned	NULL
into	NULL
the	NULL
pEBB-Nef	NULL
vector	NULL
to	NULL
generate	NULL
pEBB-Nef-ER-IRES-puro	NULL
.	NULL

Through	NULL
the	NULL
primers	NULL
used	NULL
for	NULL
PCR	NULL
,	NULL
the	NULL
stop	NULL
codon	NULL
of	NULL
Nef	NULL
was	NULL
removed	NULL
and	NULL
the	NULL
coding	NULL
sequence	NULL
was	NULL
kept	NULL
in	NULL
frame	NULL
with	NULL
the	NULL
ER	NULL
coding	NULL
sequence	NULL
.	NULL

The	NULL
N	NULL
terminus	NULL
of	NULL
Nef	NULL
was	NULL
unmodified	NULL
and	NULL
carried	NULL
its	NULL
natural	NULL
myristoylation	NULL
sequence	NULL
.	NULL

The	NULL
resulting	NULL
pEBB-Nef-ER-IRES-puro	NULL
vector	NULL
was	NULL
used	NULL
for	NULL
transfection	NULL
into	NULL
SupT1	NULL
cells	NULL
.	NULL

Transfections	NULL
.	NULL

SupT1	NULL
cells	NULL
growing	NULL
in	NULL
log	NULL
phase	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
pg	NULL
of	NULL
linearized	NULL
pEBB-Nef-ER-IRES-puro	NULL
by	NULL
electroporation	NULL
of	NULL
10	NULL
million	NULL
cells	NULL
(	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
growth	NULL
medium	NULL
)	NULL
at	NULL
250	NULL
Volts	NULL
and	NULL
1,180	NULL
F	NULL
,	NULL
using	NULL
a	NULL
CellPorator	NULL
(	NULL
GIBCO-BRL	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

;	NULL
24	NULL
h	NULL
posttransfection	NULL
,	NULL
the	NULL
SupT1	NULL
cells	NULL
were	NULL
plated	NULL
(	NULL
10,000	NULL
cells/well	NULL
)	NULL
in	NULL
96-well	NULL
plates	NULL
in	NULL
growth	NULL
medium	NULL
containing	NULL
puromycin	NULL
(	NULL
1.5	NULL
pg/ml	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

.	NULL

The	NULL
stable	NULL
clones	NULL
that	NULL
grew	NULL
were	NULL
tested	NULL
for	NULL
Nef-ER	NULL
expression	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
anti-Nef	NULL
INDUCIBLE	NULL
ACTIVATION	NULL
OF	NULL
HIV-1	NULL
Nef	NULL
FUNCTION	NULL
IN	NULL
T	NULL
CELLS	NULL
|	NULL
835	NULL
antibodies	NULL
(	NULL
pool	NULL
of	NULL
two	NULL
monoclonal	NULL
antibodies	NULL
,	NULL
SN20	NULL
and	NULL
SN41	NULL
)	NULL
(	NULL
38	NULL
)	NULL
or	NULL
anti-ER	NULL
antibody	NULL
MC-20	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Immunoprecipitations	NULL
,	NULL
immunoblotting	NULL
,	NULL
and	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
4-HT	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
lysed	NULL
using	NULL
a	NULL
lysis	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
,	NULL
10	NULL
mM	NULL
sodium	NULL
fluoride	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
10	NULL
jg	NULL
each	NULL
of	NULL
pepstatin	NULL
,	NULL
leupeptin	NULL
,	NULL
aprotinin	NULL
,	NULL
and	NULL
4-	NULL
(	NULL
2-aminocth-y	NULL
)	NULL
benzenesulfonyl	NULL
fluoride	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
or	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
where	NULL
indicated	NULL
)	NULL
.	NULL

After	NULL
spinning	NULL
out	NULL
the	NULL
nuclei	NULL
and	NULL
clearance	NULL
of	NULL
debris	NULL
at	NULL
14,000	NULL
x	NULL
g	NULL
in	NULL
a	NULL
microcentrifuge	NULL
,	NULL
the	NULL
lysates	NULL
were	NULL
mixed	NULL
with	NULL
loading	NULL
buffer	NULL
and	NULL
directly	NULL
analyzed	NULL
by	NULL
anti-Nef	NULL
or	NULL
anti-ER	NULL
immunoblotting	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-ER	NULL
antibodies	NULL
,	NULL
and	NULL
the	NULL
bound	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
immunoblotting	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

For	NULL
quantitation	NULL
of	NULL
Nef-ER	NULL
protein	NULL
level	NULL
in	NULL
Western	NULL
blots	NULL
,	NULL
after	NULL
the	NULL
primary	NULL
anti-ER	NULL
antibody	NULL
,	NULL
**	NULL
``	NULL
I-labeled	NULL
protein	NULL
A	NULL
was	NULL
used	NULL
as	NULL
a	NULL
secondary	NULL
detection	NULL
reagent	NULL
,	NULL
and	NULL
radioactivity	NULL
in	NULL
the	NULL
bands	NULL
was	NULL
quantitated	NULL
in	NULL
a	NULL
phosphorimager	NULL
.	NULL

In	NULL
vitro	NULL
kinase	NULL
assays	NULL
for	NULL
the	NULL
62-kDa	NULL
Nef-associated	NULL
kinase	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
anti-ER	NULL
immunoprecipitates	NULL
from	NULL
4-HT-treated	NULL
or	NULL
untreated	NULL
samples	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
kinase	NULL
assay	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.02	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
The	NULL
beads	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
with	NULL
10	NULL
Ci	NULL
of	NULL
[	NULL
y-°P	NULL
]	NULL
JATP	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
again	NULL
three	NULL
times	NULL
,	NULL
then	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-sample	NULL
buffer	NULL
was	NULL
added	NULL
,	NULL
the	NULL
mixture	NULL
was	NULL
boiled	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-8	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
developed	NULL
by	NULL
autoradiography	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
emetine	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
100	NULL
pg/ml	NULL
for	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
4-HT	NULL
;	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
kinase	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Monitoring	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
.	NULL

The	NULL
surface	NULL
expression	NULL
and	NULL
downmodulation	NULL
of	NULL
CD4	NULL
and	NULL
HLA-AZ2	NULL
were	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Briefly	NULL
,	NULL
untreated	NULL
and	NULL
4-HT-treated	NULL
SupT1	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
anti-CD4	NULL
(	NULL
OKT4D	NULL
)	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-labeled	NULL
anti-mouse	NULL
immunoglobulin	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
analyzed	NULL
in	NULL
a	NULL
FACScalibur	NULL
flow	NULL
cytometer	NULL
.	NULL

Alternatively	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
mouse-anti-human	NULL
CD4	NULL
(	NULL
Caltag	NULL
)	NULL
was	NULL
used	NULL
and	NULL
directly	NULL
analyzed	NULL
.	NULL

For	NULL
HLA-A2	NULL
staining	NULL
,	NULL
PE-conjugated	NULL
antibody	NULL
MA2.1	NULL
(	NULL
Caltag	NULL
)	NULL
was	NULL
used	NULL
.	NULL

For	NULL
two-color	NULL
flow	NULL
cytometry	NULL
,	NULL
anti-CD4-FITC	NULL
and	NULL
anti-HLA-A2-PE	NULL
antibodies	NULL
were	NULL
added	NULL
simultaneously	NULL
,	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
data	NULL
were	NULL
analyzed	NULL
using	NULL
the	NULL
CellQuest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

For	NULL
determining	NULL
the	NULL
percentage	NULL
of	NULL
downmodulation	NULL
,	NULL
the	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MFT	NULL
)	NULL
of	NULL
the	NULL
CD4	NULL
staining	NULL
(	NULL
or	NULL
HLA-A2	NULL
staining	NULL
)	NULL
on	NULL
untreated	NULL
SupT1	NULL
cells	NULL
was	NULL
set	NULL
as	NULL
100	NULL
%	NULL
.	NULL

The	NULL
CD4	NULL
or	NULL
HLA-A2	NULL
MFIs	NULL
at	NULL
the	NULL
different	NULL
conditions	NULL
were	NULL
compared	NULL
with	NULL
MFIs	NULL
on	NULL
untreated	NULL
cells	NULL
to	NULL
determine	NULL
the	NULL
percentage	NULL
of	NULL
downmodulation	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
at	NULL
least	NULL
10,000	NULL
events	NULL
were	NULL
collected	NULL
and	NULL
only	NULL
the	NULL
expression	NULL
on	NULL
live-gated	NULL
cells	NULL
was	NULL
analyzed	NULL
.	NULL

Isolation	NULL
of	NULL
lipid	NULL
rafts	NULL
.	NULL

Nef-ER	NULL
31	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
a	NULL
buffer	NULL
containing	NULL
25	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
30	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
,	NULL
10	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
,	NULL
and	NULL
either	NULL
0.05	NULL
%	NULL
or	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

Lysates	NULL
were	NULL
then	NULL
diluted	NULL
1:1	NULL
with	NULL
80	NULL
%	NULL
sucrose	NULL
and	NULL
transferred	NULL
into	NULL
a	NULL
Beckman	NULL
ultracentrifuge	NULL
tube	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
overlaid	NULL
by	NULL
2	NULL
ml	NULL
of	NULL
30	NULL
%	NULL
sucrose	NULL
followed	NULL
by	NULL
1	NULL
ml	NULL
of	NULL
5	NULL
%	NULL
sucrose	NULL
and	NULL
then	NULL
centrifuged	NULL
for	NULL
16	NULL
to	NULL
20	NULL
h	NULL
at	NULL
200,000	NULL
x	NULL
g	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
centrifugation	NULL
,	NULL
10	NULL
fractions	NULL
of	NULL
400	NULL
pl	NULL
each	NULL
were	NULL
removed	NULL
.	NULL

The	NULL
lipid	NULL
raft	NULL
band	NULL
visible	NULL
at	NULL
the	NULL
interface	NULL
of	NULL
30	NULL
and	NULL
5	NULL
%	NULL
sucrose	NULL
(	NULL
fraction	NULL
3	NULL
)	NULL
was	NULL
removed	NULL
and	NULL
solubilized	NULL
by	NULL
adding	NULL
50	NULL
mM	NULL
octylglucoside	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
lysate	NULL
remaining	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
tube	NULL
represented	NULL
the	NULL
Triton-soluble	NULL
fraction	NULL
.	NULL

Fractions	NULL
8	NULL
to	NULL
10	NULL
contained	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
proteins	NULL
in	NULL
nonraft	NULL
fractions	NULL
,	NULL
and	NULL
fraction	NULL
9	NULL
was	NULL
used	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

RESULTS	NULL
Design	NULL
of	NULL
the	NULL
Nef-ER	NULL
construct	NULL
and	NULL
expression	NULL
in	NULL
the	NULL
T-cell	NULL
line	NULL
SupT1	NULL
.	NULL

The	NULL
difficulty	NULL
in	NULL
obtaining	NULL
good	NULL
levels	NULL
of	NULL
Nef	NULL
protein	NULL
expression	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
Nef	NULL
's	NULL
effects	NULL
on	NULL
cellular	NULL
proliferation	NULL
and	NULL
apoptosis	NULL
(	NULL
5	NULL
,	NULL
66	NULL
)	NULL
.	NULL

To	NULL
overcome	NULL
this	NULL
difficulty	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
design	NULL
a	NULL
Nef	NULL
protein	NULL
that	NULL
would	NULL
be	NULL
inactive	NULL
basally	NULL
and	NULL
whose	NULL
function	NULL
could	NULL
be	NULL
inducibly	NULL
activated	NULL
.	NULL

To	NULL
achieve	NULL
this	NULL
,	NULL
we	NULL
engineered	NULL
a	NULL
Nef-ER	NULL
protein	NULL
that	NULL
contains	NULL
full-length	NULL
Nef	NULL
fused	NULL
at	NULL
the	NULL
C	NULL
terminus	NULL
with	NULL
the	NULL
murine	NULL
ER	NULL
hormone-binding	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
ER	NULL
of	NULL
other	NULL
cellular	NULL
proteins	NULL
836	NULL
WALK	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
EF-1	NULL
prom	NULL
.	NULL

Poly	NULL
A	NULL
Nef	NULL
ER	NULL
IRES	NULL
Puro	NULL
(	NULL
Hormone	NULL
binding	NULL
domain	NULL
)	NULL
SupT1	NULL
Nef-ER	NULL
Clone	NULL
#	NULL
gr	NULL
--	NULL
Paras	NULL
o	NULL
qo	NULL
-	NULL
240	NULL
31	NULL
62	NULL
kDa	NULL
-	NULL
coum	NULL
commer	NULL
cong	NULL
|	NULL
4~	NULL
Nef-ER	NULL
Total	NULL
lysates	NULL
Blot	NULL
:	NULL
anti-ER	NULL
C	NULL
SupT1	NULL
Parental	NULL
__Line	NULL
Nef-ER	NULL
Clone	NULL
#	NULL
_31	NULL
_	NULL
4-HT	NULL
:	NULL
_+	NULL
_-	NULL
+05	NULL
&	NULL
_	NULL
>	NULL
Blot	NULL
:	NULL
Anti-Nef	NULL
Nef-ER	NULL
#	NULL
31	NULL
100	NULL
1	NULL
$	NULL
(	NULL
e	NULL
50	NULL
7	NULL
I—I	NULL
fu	NULL
:	NULL
0	NULL
10pM	NULL
_	NULL
100pM	NULL
_	NULL
{	NULL
nM	NULL
10nM	NULL
_	NULL
100nM	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Expression	NULL
of	NULL
Nef-ER	NULL
in	NULL
SupT1	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
the	NULL
Nef-ER-IRES-Puro	NULL
construct	NULL
.	NULL

NL43	NULL
Nef	NULL
was	NULL
fused	NULL
at	NULL
its	NULL
C	NULL
terminus	NULL
in	NULL
frame	NULL
to	NULL
the	NULL
hormone-binding	NULL
region	NULL
of	NULL
murine	NULL
ER	NULL
.	NULL

This	NULL
Nef-ER	NULL
was	NULL
expressed	NULL
under	NULL
the	NULL
elongation	NULL
EF-l	NULL
«	NULL
promoter	NULL
(	NULL
EF-1	NULL
prom	NULL
.	NULL
)	NULL

as	NULL
a	NULL
bicistronic	NULL
message	NULL
with	NULL
an	NULL
IRES	NULL
separating	NULL
the	NULL
puromycin	NULL
resistance	NULL
gene	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Expression	NULL
of	NULL
Nef-ER	NULL
in	NULL
stably	NULL
transfected	NULL
SupT1	NULL
clones	NULL
and	NULL
the	NULL
parental	NULL
SupT1	NULL
line	NULL
was	NULL
analyzed	NULL
by	NULL
anti-ER	NULL
immunoblotting	NULL
of	NULL
total	NULL
cellular	NULL
lysates	NULL
.	NULL

(	NULL
C	NULL
)	NULL
To	NULL
determine	NULL
the	NULL
expression	NULL
of	NULL
Nef-ER	NULL
protein	NULL
before	NULL
and	NULL
after	NULL
4-HT	NULL
treatment	NULL
(	NULL
1	NULL
M	NULL
for	NULL
24	NULL
h	NULL
)	NULL
,	NULL
total	NULL
lysates	NULL
from	NULL
two	NULL
SupT1	NULL
clones	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-Nef	NULL
antibody	NULL
.	NULL

There	NULL
was	NULL
an	NULL
increase	NULL
in	NULL
Nef-ER	NULL
protein	NULL
seen	NULL
after	NULL
4-HT	NULL
treatment	NULL
.	NULL

No	NULL
band	NULL
corresponding	NULL
to	NULL
Nef	NULL
alone	NULL
was	NULL
seen	NULL
in	NULL
untreated	NULL
or	NULL
treated	NULL
SupT1	NULL
clones	NULL
.	NULL

(	NULL
D	NULL
)	NULL
To	NULL
further	NULL
characterize	NULL
the	NULL
increase	NULL
in	NULL
Nef-ER	NULL
levels	NULL
,	NULL
SupT1	NULL
cells	NULL
(	NULL
clone	NULL
31	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
16	NULL
h.	NULL
The	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-ER	NULL
,	NULL
and	NULL
the	NULL
blots	NULL
were	NULL
developed	NULL
by	NULL
using	NULL
'	NULL
``	NULL
I-labeled	NULL
protein	NULL
A	NULL
.	NULL

The	NULL
radioactive	NULL
counts	NULL
in	NULL
the	NULL
different	NULL
lanes	NULL
were	NULL
determined	NULL
in	NULL
a	NULL
phosphorimager	NULL
.	NULL

After	NULL
subtraction	NULL
of	NULL
background	NULL
radioactive	NULL
counts	NULL
(	NULL
from	NULL
another	NULL
part	NULL
of	NULL
the	NULL
same	NULL
gel	NULL
)	NULL
,	NULL
the	NULL
value	NULL
for	NULL
the	NULL
lane	NULL
without	NULL
4-HT	NULL
treatment	NULL
was	NULL
set	NULL
at	NULL
100	NULL
%	NULL
,	NULL
and	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
data	NULL
were	NULL
plotted	NULL
accordingly	NULL
.	NULL

%	NULL
of	NULL
No	NULL
Treatment	NULL
Control	NULL
(	NULL
such	NULL
as	NULL
hsp90	NULL
)	NULL
sterically	NULL
hinders	NULL
the	NULL
function	NULL
of	NULL
proteins	NULL
fused	NULL
to	NULL
the	NULL
ER	NULL
(	NULL
31	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
membrane-permeable	NULL
estrogen	NULL
analogue	NULL
4-HT	NULL
to	NULL
the	NULL
ER	NULL
opens	NULL
up	NULL
the	NULL
protein	NULL
and	NULL
relieves	NULL
this	NULL
inhibition	NULL
(	NULL
30	NULL
,	NULL
31	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Although	NULL
ER	NULL
fusions	NULL
have	NULL
not	NULL
been	NULL
tested	NULL
for	NULL
viral	NULL
or	NULL
toxic	NULL
proteins	NULL
such	NULL
as	NULL
Nef	NULL
,	NULL
given	NULL
that	NULL
specific	NULL
regions	NULL
within	NULL
Nef	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
specific	NULL
Nef-mediated	NULL
effects	NULL
,	NULL
we	NULL
predicted	NULL
that	NULL
Nef	NULL
fused	NULL
to	NULL
the	NULL
ER	NULL
may	NULL
also	NULL
be	NULL
kept	NULL
inactive	NULL
and	NULL
could	NULL
be	NULL
inducibly	NULL
activated	NULL
.	NULL

The	NULL
design	NULL
of	NULL
the	NULL
Nef-ER	NULL
construct	NULL
and	NULL
its	NULL
transfection	NULL
into	NULL
the	NULL
SupT1	NULL
cells	NULL
were	NULL
performed	NULL
as	NULL
detailed	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Stable	NULL
puromycin-resistant	NULL
clones	NULL
were	NULL
selected	NULL
and	NULL
J.	NULL
Virou	NULL
.	NULL

screened	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
Nef-ER	NULL
fusion	NULL
protein	NULL
(	NULL
~60	NULL
kDa	NULL
)	NULL
by	NULL
anti-ER	NULL
immunoblotting	NULL
of	NULL
total	NULL
cellular	NULL
lysates	NULL
.	NULL

Several	NULL
clones	NULL
expressing	NULL
different	NULL
levels	NULL
of	NULL
Nef-ER	NULL
were	NULL
identified	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Anti-ER	NULL
immunoprecipitation	NULL
followed	NULL
by	NULL
anti-Nef	NULL
immunoblotting	NULL
confirmed	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
~60-kDa	NULL
band	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
as	NULL
Nef-ER	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
parental	NULL
SupT1	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
the	NULL
Nef-ER	NULL
protein	NULL
.	NULL

Since	NULL
most	NULL
of	NULL
the	NULL
puromycin-resistant	NULL
clones	NULL
expressed	NULL
the	NULL
Nef-ER	NULL
protein	NULL
,	NULL
there	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
selection	NULL
against	NULL
basal	NULL
Nef-ER	NULL
expression	NULL
.	NULL

These	NULL
data	NULL
suggested	NULL
that	NULL
Nef-ER	NULL
could	NULL
be	NULL
readily	NULL
expressed	NULL
in	NULL
SupT1	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
anti-Nef	NULL
immunoblotting	NULL
of	NULL
the	NULL
total	NULL
cell	NULL
lysates	NULL
revealed	NULL
no	NULL
unique	NULL
band	NULL
corresponding	NULL
to	NULL
Nef	NULL
alone	NULL
before	NULL
or	NULL
after	NULL
4-HT	NULL
addition	NULL
in	NULL
Nef-ER-expressing	NULL
cells	NULL
compared	NULL
to	NULL
the	NULL
parental	NULL
SupT1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

For	NULL
the	NULL
assays	NULL
discussed	NULL
in	NULL
the	NULL
rest	NULL
of	NULL
this	NULL
report	NULL
,	NULL
multiple	NULL
Nef-ER	NULL
expressing	NULL
clones	NULL
were	NULL
routinely	NULL
analyzed	NULL
and	NULL
representative	NULL
data	NULL
are	NULL
presented	NULL
.	NULL

For	NULL
initial	NULL
characterization	NULL
of	NULL
Nef-ER	NULL
expression	NULL
in	NULL
stable	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
examined	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
before	NULL
and	NULL
after	NULL
addition	NULL
of	NULL
4-HT	NULL
in	NULL
a	NULL
time	NULL
course	NULL
.	NULL

While	NULL
Nef-ER	NULL
expression	NULL
was	NULL
readily	NULL
detected	NULL
before	NULL
4-HT	NULL
addition	NULL
,	NULL
surprisingly	NULL
,	NULL
the	NULL
Nef-ER	NULL
level	NULL
increased	NULL
somewhat	NULL
over	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
used	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
16	NULL
h	NULL
and	NULL
monitored	NULL
the	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
.	NULL

In	NULL
this	NULL
exper-iment	NULL
,	NULL
to	NULL
obtain	NULL
more	NULL
accurate	NULL
protein	NULL
quantitation	NULL
,	NULL
we	NULL
used	NULL
``	NULL
I-labeled	NULL
protein	NULL
A	NULL
as	NULL
a	NULL
secondary	NULL
detection	NULL
reagent	NULL
in	NULL
the	NULL
Western	NULL
blot	NULL
(	NULL
instead	NULL
of	NULL
enhanced	NULL
chemiluminescence	NULL
)	NULL
.	NULL

Counting	NULL
of	NULL
the	NULL
radioactivity	NULL
in	NULL
the	NULL
bands	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
Nef-ER	NULL
protein	NULL
level	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
4-HT	NULL
that	NULL
peaked	NULL
at	NULL
10	NULL
nM	NULL
4-HT	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

Our	NULL
working	NULL
hypothesis	NULL
is	NULL
that	NULL
the	NULL
Nef-ER	NULL
may	NULL
be	NULL
less	NULL
stable	NULL
or	NULL
degraded	NULL
more	NULL
rapidly	NULL
prior	NULL
to	NULL
4-HT	NULL
binding	NULL
to	NULL
the	NULL
ER	NULL
domain	NULL
.	NULL

Such	NULL
a	NULL
fortuitous	NULL
modulation	NULL
of	NULL
the	NULL
Nef-ER	NULL
protein	NULL
level	NULL
may	NULL
provide	NULL
another	NULL
level	NULL
of	NULL
regulation	NULL
of	NULL
this	NULL
construct	NULL
.	NULL

Inducible	NULL
association	NULL
of	NULL
Nef-ER	NULL
with	NULL
NAK	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
indicated	NULL
that	NULL
Nef	NULL
associates	NULL
with	NULL
a	NULL
62-kDa	NULL
serine/threonine	NULL
kinase	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
NAK	NULL
[	NULL
Nef-associated	NULL
kinase	NULL
]	NULL
)	NULL
and	NULL
that	NULL
NAK	NULL
may	NULL
facilitate	NULL
HIV	NULL
pathogenesis	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
identity	NULL
of	NULL
NAK	NULL
is	NULL
unclear	NULL
,	NULL
three	NULL
groups	NULL
have	NULL
identified	NULL
it	NULL
to	NULL
be	NULL
a	NULL
member	NULL
of	NULL
the	NULL
PAK	NULL
family	NULL
(	NULL
16	NULL
,	NULL
44	NULL
,	NULL
52	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
Nef-ER	NULL
is	NULL
functional	NULL
,	NULL
we	NULL
tested	NULL
its	NULL
ability	NULL
to	NULL
coprecipitate	NULL
the	NULL
62-kDa	NULL
phosphoprotein	NULL
.	NULL

We	NULL
examined	NULL
this	NULL
by	NULL
precipitating	NULL
Nef-ER	NULL
before	NULL
and	NULL
after	NULL
4-HT	NULL
addition	NULL
followed	NULL
by	NULL
an	NULL
in	NULL
vitro	NULL
autophosphorylation	NULL
kinase	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
no	NULL
labeled	NULL
band	NULL
was	NULL
coprecipitated	NULL
from	NULL
parental	NULL
cells	NULL
or	NULL
Nef-ER	NULL
cells	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
4-HT	NULL
.	NULL

However	NULL
,	NULL
as	NULL
little	NULL
as	NULL
15	NULL
min	NULL
after	NULL
4-HT	NULL
addition	NULL
,	NULL
we	NULL
could	NULL
detect	NULL
an	NULL
inducible	NULL
association	NULL
of	NULL
Nef-ER	NULL
with	NULL
a	NULL
62-kDa	NULL
phosphopro-tein	NULL
,	NULL
and	NULL
this	NULL
association	NULL
was	NULL
enhanced	NULL
2	NULL
and	NULL
4	NULL
h	NULL
after	NULL
4-HT	NULL
treatment	NULL
.	NULL

Immunoblotting	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
with	NULL
anti-PAK	NULL
and	NULL
anti-ER	NULL
revealed	NULL
that	NULL
the	NULL
band	NULL
corresponding	NULL
to	NULL
PAK	NULL
migrates	NULL
slower	NULL
than	NULL
Nef-ER	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
the	NULL
62-kDa	NULL
phosphorylated	NULL
band	NULL
is	NULL
most	NULL
likely	NULL
NAK	NULL
that	NULL
became	NULL
auto-phosphorylated	NULL
and	NULL
not	NULL
the	NULL
Nef-ER	NULL
itself	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
then	NULL
determined	NULL
if	NULL
the	NULL
NAK	NULL
binding	NULL
occurs	NULL
with	NULL
the	NULL
existing	NULL
Nef-ER	NULL
proteins	NULL
that	NULL
are	NULL
inducibly	NULL
activated	NULL
or	NULL
with	NULL
newly	NULL
synthesized	NULL
Nef-ER	NULL
molecules	NULL
.	NULL

We	NULL
treated	NULL
cells	NULL
first	NULL
with	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
emetine	NULL
and	NULL
then	NULL
added	NULL
4-HT	NULL
and	NULL
assessed	NULL
the	NULL
Nef-ER/NAK	NULL
interaction	NULL
by	NULL
the	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
A	NULL
Parental	NULL
Line	NULL
Nef-ER	NULL
#	NULL
31	NULL
--	NULL
-0	NULL
4h	NULL
0	NULL
15m	NULL
2h	NULL
4h	NULL
ist	NULL
62	NULL
kDa	NULL
-	NULL
<	NULL
-	NULL
PAK	NULL
B	NULL
Emetine	NULL
:	NULL
_	NULL
-	NULL
-	NULL
+	NULL
+	NULL
4-HT	NULL
:	NULL
-	NULL
+	NULL
-	NULL
+	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

4-HT-dependent	NULL
coprecipitation	NULL
of	NULL
kinase	NULL
activity	NULL
with	NULL
Nef-ER	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Parental	NULL
or	NULL
Nef-ER	NULL
31	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
4-HT	NULL
for	NULL
15	NULL
min	NULL
,	NULL
2	NULL
h	NULL
,	NULL
or	NULL
4	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-ER	NULL
antibody	NULL
,	NULL
and	NULL
the	NULL
coprecipitating	NULL
kinase	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Nef-ER	NULL
31	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
emetine	NULL
(	NULL
100	NULL
pg/ml	NULL
!	NULL
)	NULL

for	NULL
5	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
1	NULL
wM	NULL
4-HT	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
ER	NULL
immunoprecipitation	NULL
and	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
were	NULL
performed	NULL
as	NULL
for	NULL
panel	NULL
A.	NULL
emetine	NULL
,	NULL
addition	NULL
of	NULL
4-HT	NULL
led	NULL
to	NULL
coprecipitation	NULL
of	NULL
Nef-ER	NULL
with	NULL
NAK	NULL
,	NULL
suggesting	NULL
an	NULL
inducible	NULL
association	NULL
of	NULL
NAK	NULL
with	NULL
existing	NULL
Nef-ER	NULL
molecules	NULL
.	NULL

Emetine	NULL
was	NULL
functional	NULL
under	NULL
these	NULL
conditions	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
its	NULL
inhibition	NULL
of	NULL
[	NULL
°*°SJmethi-onine	NULL
incorporation	NULL
into	NULL
cellular	NULL
proteins	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Our	NULL
attempts	NULL
to	NULL
blot	NULL
for	NULL
PAK	NULL
(	NULL
using	NULL
a	NULL
pan-PAK	NULL
antibody	NULL
)	NULL
in	NULL
the	NULL
Nef-ER	NULL
immunoprecipitates	NULL
before	NULL
and	NULL
after	NULL
4-HT	NULL
addition	NULL
were	NULL
unsuccessful	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
difficulty	NULL
in	NULL
detecting	NULL
PAK	NULL
by	NULL
immunoblotting	NULL
reported	NULL
by	NULL
others	NULL
(	NULL
16	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
can	NULL
not	NULL
distinguish	NULL
between	NULL
the	NULL
possibilities	NULL
that	NULL
Nef-ER	NULL
interacts	NULL
with	NULL
NAK	NULL
only	NULL
after	NULL
4-HT	NULL
binding	NULL
and	NULL
that	NULL
NAK	NULL
is	NULL
already	NULL
bound	NULL
to	NULL
the	NULL
Nef-ER	NULL
but	NULL
is	NULL
inactive	NULL
until	NULL
4-HT	NULL
addition	NULL
.	NULL

Nevertheless	NULL
,	NULL
these	NULL
data	NULL
indicated	NULL
that	NULL
Nef-ER	NULL
is	NULL
functional	NULL
and	NULL
that	NULL
it	NULL
can	NULL
be	NULL
inducibly	NULL
activated	NULL
in	NULL
a	NULL
T-cell	NULL
line	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
SupT1	NULL
cells	NULL
,	NULL
we	NULL
obtained	NULL
stable	NULL
clones	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
expressing	NULL
Nef-ER	NULL
.	NULL

Again	NULL
,	NULL
addition	NULL
of	NULL
4-HT	NULL
for	NULL
15	NULL
min	NULL
led	NULL
to	NULL
inducible	NULL
coprecipitation	NULL
of	NULL
NAK	NULL
with	NULL
the	NULL
Nef-ER	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Inducible	NULL
association	NULL
of	NULL
Nef-ER	NULL
with	NULL
lipid	NULL
rafts	NULL
.	NULL

Cholester-ol-enriched	NULL
membrane	NULL
microdomains	NULL
,	NULL
known	NULL
as	NULL
lipid	NULL
rafts	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
important	NULL
in	NULL
initiation	NULL
and	NULL
full	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
antigen	NULL
(	NULL
25	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
previous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
Nef	NULL
can	NULL
activate	NULL
certain	NULL
cellular	NULL
signaling	NULL
events	NULL
that	NULL
mimic	NULL
T-cell	NULL
activation	NULL
(	NULL
39	NULL
,	NULL
66	NULL
)	NULL
.	NULL

We	NULL
hypothesized	NULL
that	NULL
Nef	NULL
may	NULL
localize	NULL
to	NULL
such	NULL
membrane	NULL
microdomains	NULL
if	NULL
it	NULL
were	NULL
to	NULL
initiate	NULL
T-cell	NULL
signaling	NULL
events	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
isolated	NULL
the	NULL
lipid	NULL
raft	NULL
fraction	NULL
by	NULL
sucrose	NULL
gradient	NULL
ultracentrifugation	NULL
before	NULL
and	NULL
after	NULL
2-h	NULL
4-HT	NULL
treatment	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
for	NULL
details	NULL
)	NULL
(	NULL
3	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
presence	NULL
of	NULL
Nef-ER	NULL
in	NULL
the	NULL
raft	NULL
and	NULL
nonraft	NULL
fractions	NULL
by	NULL
immunoblotting	NULL
.	NULL

We	NULL
could	NULL
detect	NULL
an	NULL
inducible	NULL
localization	NULL
of	NULL
Nef-ER	NULL
to	NULL
the	NULL
lipid	NULL
raft	NULL
fraction	NULL
upon	NULL
4-HT	NULL
addition	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Nef-ER	NULL
could	NULL
also	NULL
be	NULL
detected	NULL
readily	NULL
in	NULL
the	NULL
nonraft	NULL
or	NULL
Triton-soluble	NULL
fraction	NULL
.	NULL

Although	NULL
localization	NULL
of	NULL
some	NULL
proteins	NULL
to	NULL
rafts	NULL
is	NULL
sensitive	NULL
to	NULL
detergent	NULL
concentration	NULL
used	NULL
(	NULL
3	NULL
)	NULL
,	NULL
we	NULL
could	NULL
detect	NULL
Nef-ER	NULL
in	NULL
the	NULL
rafts	NULL
after	NULL
lysis	NULL
of	NULL
cells	NULL
at	NULL
both	NULL
0.05	NULL
and	NULL
0.5	NULL
%	NULL
Triton	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
quality	NULL
of	NULL
the	NULL
raft	NULL
preparation	NULL
was	NULL
confirmed	NULL
by	NULL
blotting	NULL
for	NULL
Lck	NULL
,	NULL
a	NULL
dually	NULL
acy-	NULL
INDUCIBLE	NULL
ACTIVATION	NULL
OF	NULL
HIV-1	NULL
Nef	NULL
FUNCTION	NULL
IN	NULL
T	NULL
CELLS	NULL
-	NULL
837	NULL
lated	NULL
T-cell	NULL
kinase	NULL
that	NULL
has	NULL
been	NULL
known	NULL
to	NULL
localize	NULL
to	NULL
the	NULL
rafts	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
bottom	NULL
panel	NULL
)	NULL
(	NULL
24	NULL
,	NULL
64	NULL
)	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
unlike	NULL
Lok	NULL
,	NULL
which	NULL
have	NULL
two	NULL
acylation	NULL
sites	NULL
in	NULL
its	NULL
N	NULL
terminus	NULL
,	NULL
the	NULL
primary	NULL
sequence	NULL
of	NULL
Nef	NULL
carries	NULL
only	NULL
a	NULL
single	NULL
myristoylation	NULL
site	NULL
.	NULL

Since	NULL
dually	NULL
acylated	NULL
proteins	NULL
target	NULL
to	NULL
the	NULL
rafts	NULL
much	NULL
more	NULL
efficiently	NULL
than	NULL
singly	NULL
acylated	NULL
proteins	NULL
(	NULL
7	NULL
)	NULL
,	NULL
this	NULL
may	NULL
be	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
smaller	NULL
fraction	NULL
of	NULL
total	NULL
Nef-ER	NULL
in	NULL
the	NULL
raft	NULL
fraction	NULL
.	NULL

Nevertheless	NULL
,	NULL
since	NULL
the	NULL
protein	NULL
content	NULL
in	NULL
rafts	NULL
generally	NULL
represents	NULL
to	NULL
0.3	NULL
to	NULL
1	NULL
%	NULL
of	NULL
total	NULL
proteins	NULL
in	NULL
the	NULL
nonraft	NULL
fraction	NULL
,	NULL
the	NULL
data	NULL
may	NULL
suggest	NULL
an	NULL
enrichment	NULL
of	NULL
Nef-ER	NULL
in	NULL
the	NULL
rafts	NULL
.	NULL

The	NULL
movement	NULL
of	NULL
proteins	NULL
to	NULL
the	NULL
lipid	NULL
rafts	NULL
has	NULL
been	NULL
correlated	NULL
with	NULL
their	NULL
specific	NULL
function	NULL
in	NULL
lymphocytes	NULL
(	NULL
25	NULL
,	NULL
34	NULL
)	NULL
,	NULL
and	NULL
the	NULL
localization	NULL
of	NULL
Nef-ER	NULL
may	NULL
be	NULL
important	NULL
for	NULL
Nef	NULL
function	NULL
.	NULL

Recently	NULL
,	NULL
another	NULL
group	NULL
has	NULL
also	NULL
shown	NULL
that	NULL
a	NULL
fraction	NULL
of	NULL
Nef	NULL
localizes	NULL
to	NULL
rafts	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Inducible	NULL
Nef-ER	NULL
mediates	NULL
downmodulation	NULL
of	NULL
CD4	NULL
.	NULL

We	NULL
monitored	NULL
Nef-mediated	NULL
downmodulation	NULL
of	NULL
cell	NULL
surface	NULL
CD4	NULL
by	NULL
flow	NULL
cytometry	NULL
with	NULL
and	NULL
without	NULL
4-HT	NULL
(	NULL
1	NULL
M	NULL
for	NULL
24	NULL
h	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
4-HT	NULL
alone	NULL
did	NULL
not	NULL
affect	NULL
CD4	NULL
surface	NULL
expression	NULL
,	NULL
as	NULL
there	NULL
was	NULL
no	NULL
downmodulation	NULL
on	NULL
parental	NULL
SupT1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
Nef-ER-expressing	NULL
clones	NULL
,	NULL
surface	NULL
level	NULL
of	NULL
CD4	NULL
was	NULL
dramatically	NULL
downmodulated	NULL
after	NULL
4-HT	NULL
addition	NULL
compared	NULL
to	NULL
no	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
a	NULL
time	NULL
course	NULL
,	NULL
the	NULL
downmodulation	NULL
of	NULL
CD4	NULL
could	NULL
be	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
2	NULL
h	NULL
after	NULL
4-HT	NULL
addition	NULL
and	NULL
was	NULL
nearly	NULL
maximal	NULL
in	NULL
4	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

4-HT	NULL
dose-dependent	NULL
downmodulation	NULL
of	NULL
CD4	NULL
by	NULL
Nef-ER	NULL
.	NULL

We	NULL
then	NULL
determined	NULL
the	NULL
kinetics	NULL
of	NULL
CD4	NULL
downmodulation	NULL
by	NULL
Nef-ER	NULL
in	NULL
response	NULL
to	NULL
increasing	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

Initially	NULL
,	NULL
we	NULL
tested	NULL
if	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
would	NULL
cause	NULL
various	NULL
degrees	NULL
of	NULL
CD4	NULL
downmodulation	NULL
in	NULL
a	NULL
fixed	NULL
time	NULL
of	NULL
24	NULL
h.	NULL
Data	NULL
from	NULL
two	NULL
different	NULL
Nef-ER	NULL
clones	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
.	NULL

In	NULL
Nef-ER	NULL
2	NULL
,	NULL
1	NULL
wM	NULL
and	NULL
100	NULL
nM	NULL
4-HT	NULL
caused	NULL
maximal	NULL
CD4	NULL
downmodulation	NULL
,	NULL
while	NULL
10	NULL
nM	NULL
caused	NULL
a	NULL
partial	NULL
downmodulation	NULL
.	NULL

In	NULL
comparison	NULL
,	NULL
Nef-ER	NULL
31	NULL
had	NULL
maximal	NULL
downmodulation	NULL
at	NULL
all	NULL
concentrations	NULL
tested	NULL
(	NULL
possibly	NULL
due	NULL
to	NULL
higher	NULL
Nef-ER	NULL
protein	NULL
expression	NULL
[	NULL
see	NULL
Fig	NULL
.	NULL

1B	NULL
]	NULL
)	NULL
.	NULL

Another	NULL
clone	NULL
,	NULL
Nef-ER	NULL
10	NULL
,	NULL
was	NULL
similar	NULL
to	NULL
clone	NULL
2	NULL
in	NULL
CD4	NULL
downmodulation	NULL
in	NULL
this	NULL
experiment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
de-	NULL
Fraction	NULL
:	NULL
-	NULL
Rafts	NULL
-	NULL
|	NULL
Non-Rafts	NULL
anm	NULL
:	NULL
+	NULL
|-	NULL
|	NULL
+	NULL
[	NULL
-_	NULL
67	NULL
kDa	NULL
«	NULL
-	NULL
Nef-ER	NULL
Blot	NULL
:	NULL
anti-Nef	NULL
<	NULL
-	NULL
Lok	NULL
56kDa—	NULL
‘	NULL
.	NULL

Blot	NULL
:	NULL
anti-Lck	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Nef-ER	NULL
localizes	NULL
to	NULL
lipid	NULL
rafts	NULL
upon	NULL
activation	NULL
.	NULL

Nef-ER	NULL
31	NULL
was	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
0.5	NULL
wM	NULL
4-HT	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
the	NULL
raft	NULL
and	NULL
nonraft	NULL
fractions	NULL
were	NULL
separated	NULL
by	NULL
sucrose	NULL
gradient	NULL
ultracentrifugation	NULL
.	NULL

The	NULL
fractions	NULL
corresponding	NULL
to	NULL
rafts	NULL
and	NULL
nonrafts	NULL
(	NULL
3	NULL
and	NULL
9	NULL
,	NULL
respectively	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
with	NULL
the	NULL
anti-Nef	NULL
antibody	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-Lck	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

Experiments	NULL
performed	NULL
after	NULL
4	NULL
or	NULL
24	NULL
h	NULL
of	NULL
4-HT	NULL
treatment	NULL
gave	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

838	NULL
WALK	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
5	NULL
Parental	NULL
e	NULL
Nef-ER	NULL
#	NULL
2	NULL
o	NULL
Nef-ER	NULL
#	NULL
31	NULL
8	NULL
&	NULL
8	NULL
No	NULL
tt	NULL
Nott	NULL
)	NULL
Nott	NULL
]	NULL
|	NULL
4	NULL
,	NULL
j	NULL
_	NULL
4-HT	NULL
2	NULL
4-HT	NULL
J	NULL
a	NULL
4-HT	NULL
a	NULL
v/	NULL
o	NULL
``	NULL
£	NULL
g	NULL
Aa	NULL
.	NULL

5	NULL
Go	NULL
2	NULL
%	NULL
.	NULL

ih	NULL
oas	NULL
as	NULL
ad	NULL
an	NULL
10	NULL
%	NULL
ao	NULL
)	NULL
aot	NULL
aot	NULL
aot	NULL
10	NULL
%	NULL
ao	NULL
)	NULL
aot	NULL
ad	NULL
ant	NULL
<	NULL
--	NULL
-	NULL
_	NULL
Anti-CD4	NULL
Fluorescence	NULL
Intensity	NULL
_	NULL
--	NULL
--	NULL
--	NULL
-	NULL
»	NULL
B	NULL
Nef-ER	NULL
#	NULL
31	NULL
&	NULL
S	NULL
g	NULL
3	NULL
14	NULL
,	NULL
24	NULL
,	NULL
48	NULL
hrs	NULL
.	NULL

4	NULL
hrs	NULL
.	NULL

din	NULL
Counts	NULL
120	NULL
80	NULL
40	NULL
0	NULL
102	NULL
10°	NULL
Anti-CD4	NULL
Fluorescence	NULL
Intensity	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

4-HT	NULL
causes	NULL
Nef-ER-dependent	NULL
downmodulation	NULL
of	NULL
CD4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Parental	NULL
SupT1	NULL
cells	NULL
or	NULL
two	NULL
Nef-ER-expressing	NULL
clones	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
No	NULL
trt	NULL
.	NULL
)	NULL

or	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
4-HT	NULL
for	NULL
24	NULL
h.	NULL
The	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
was	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
unlabeled	NULL
anti-CD4	NULL
antibody	NULL
followed	NULL
by	NULL
PE-labeled	NULL
anti-mouse	NULL
immunoglobulin	NULL
.	NULL

Data	NULL
collected	NULL
from	NULL
10,000	NULL
cells	NULL
,	NULL
gated	NULL
on	NULL
the	NULL
live	NULL
cells	NULL
,	NULL
are	NULL
presented	NULL
as	NULL
a	NULL
histogram	NULL
.	NULL

The	NULL
anti-mouse	NULL
secondary	NULL
antibody	NULL
alone	NULL
served	NULL
as	NULL
the	NULL
control	NULL
(	NULL
solid	NULL
histogram	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
fluorescence	NULL
intensity	NULL
on	NULL
the	NULL
x	NULL
axis	NULL
is	NULL
shown	NULL
in	NULL
log	NULL
scale	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Nef-ER	NULL
31	NULL
was	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
4-HT	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
and	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
was	NULL
analyzed	NULL
using	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
for	NULL
panel	NULL
A	NULL
.	NULL

After	NULL
staggering	NULL
the	NULL
addition	NULL
of	NULL
4-HT	NULL
,	NULL
CD4	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
different	NULL
samples	NULL
were	NULL
performed	NULL
together	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

termine	NULL
conditions	NULL
that	NULL
induce	NULL
50	NULL
%	NULL
CD4	NULL
downmodulation	NULL
,	NULL
we	NULL
monitored	NULL
CD4	NULL
expression	NULL
after	NULL
addition	NULL
of	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
and	NULL
at	NULL
two	NULL
different	NULL
time	NULL
points	NULL
after	NULL
4-HT	NULL
addition	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

For	NULL
estimating	NULL
the	NULL
percent	NULL
downmodulation	NULL
,	NULL
the	NULL
MFI	NULL
of	NULL
CD4	NULL
in	NULL
untreated	NULL
cells	NULL
was	NULL
set	NULL
at	NULL
100	NULL
%	NULL
and	NULL
the	NULL
MFI	NULL
of	NULL
CD4	NULL
at	NULL
the	NULL
different	NULL
4-HT	NULL
treatment	NULL
points	NULL
was	NULL
used	NULL
to	NULL
estimate	NULL
the	NULL
extent	NULL
of	NULL
downmodulation	NULL
.	NULL

Several	NULL
points	NULL
can	NULL
be	NULL
noted	NULL
from	NULL
data	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
.	NULL

First	NULL
,	NULL
CD4	NULL
downmodulation	NULL
could	NULL
be	NULL
achieved	NULL
with	NULL
as	NULL
little	NULL
as	NULL
100	NULL
pM	NULL
4-HT	NULL
and	NULL
reached	NULL
a	NULL
maximum	NULL
at	NULL
about	NULL
100	NULL
nM	NULL
.	NULL

The	NULL
50	NULL
%	NULL
downmodulation	NULL
was	NULL
achieved	NULL
at	NULL
1	NULL
to	NULL
2	NULL
nM	NULL
4-HT	NULL
in	NULL
16	NULL
h.	NULL
In	NULL
similar	NULL
experiments	NULL
performed	NULL
with	NULL
Nef-ER	NULL
2	NULL
and	NULL
10	NULL
,	NULL
we	NULL
obtained	NULL
50	NULL
%	NULL
downmodulation	NULL
between	NULL
2	NULL
and	NULL
5	NULL
nM	NULL
4-HT	NULL
in	NULL
both	NULL
cases	NULL
in	NULL
16	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
seen	NULL
earlier	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
at	NULL
1	NULL
pM	NULL
4-HT	NULL
the	NULL
CD4	NULL
downmodulation	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
as	NULL
little	NULL
as	NULL
2	NULL
h.	NULL
Second	NULL
,	NULL
the	NULL
Nef-ER-mediated	NULL
downmodulation	NULL
appears	NULL
to	NULL
reach	NULL
an	NULL
equilibrium	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
4-HT	NULL
concentration	NULL
and	NULL
is	NULL
not	NULL
further	NULL
increased	NULL
by	NULL
longer	NULL
incubation	NULL
with	NULL
4-HT	NULL
.	NULL

For	NULL
example	NULL
,	NULL
100	NULL
pM	NULL
causes	NULL
about	NULL
35	NULL
%	NULL
downmodulation	NULL
of	NULL
CD4	NULL
in	NULL
16	NULL
h	NULL
and	NULL
remains	NULL
the	NULL
same	NULL
at	NULL
48	NULL
h.	NULL
This	NULL
suggests	NULL
that	NULL
there	NULL
is	NULL
a	NULL
direct	NULL
correlation	NULL
between	NULL
the	NULL
amount	NULL
of	NULL
active	NULL
Nef-ER	NULL
molecules	NULL
within	NULL
cells	NULL
(	NULL
due	NULL
to	NULL
4-HT	NULL
addition	NULL
)	NULL
and	NULL
the	NULL
extent	NULL
of	NULL
CD4	NULL
downmodulation	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
number	NULL
of	NULL
Nef	NULL
molecules	NULL
expressed	NULL
during	NULL
a	NULL
viral	NULL
infection	NULL
at	NULL
J.	NULL
Virou	NULL
.	NULL

a	NULL
given	NULL
time	NULL
could	NULL
affect	NULL
the	NULL
extent	NULL
of	NULL
CD4	NULL
downmodulation	NULL
and	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
have	NULL
consequences	NULL
for	NULL
the	NULL
infection	NULL
.	NULL

Nef-ER-mediated	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
.	NULL

Nef	NULL
is	NULL
also	NULL
known	NULL
to	NULL
downmodulate	NULL
the	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
antigen	NULL
HLA-AZ	NULL
from	NULL
HIV-1-infected	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
such	NULL
downmodulation	NULL
is	NULL
a	NULL
mechanism	NULL
that	NULL
allows	NULL
infected	NULL
cells	NULL
to	NULL
evade	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
since	NULL
cells	NULL
expressing	NULL
Nef	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
resist	NULL
HLA-restricted	NULL
cytotoxic	NULL
T-lymphocyte	NULL
lysis	NULL
(	NULL
12	NULL
to	NULL
14	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
HLA	NULL
and	NULL
CD4	NULL
downmodulation	NULL
require	NULL
different	NULL
Nef	NULL
domains	NULL
and	NULL
utilize	NULL
different	NULL
mechanisms	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
46	NULL
,	NULL
47	NULL
,	NULL
49	NULL
,	NULL
54	NULL
)	NULL
.	NULL

We	NULL
wanted	NULL
to	NULL
use	NULL
the	NULL
Nef-ER	NULL
system	NULL
to	NULL
carefully	NULL
compare	NULL
the	NULL
kinetics	NULL
of	NULL
downmodulation	NULL
of	NULL
the	NULL
two	NULL
molecules	NULL
.	NULL

Addition	NULL
of	NULL
4-HT	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
HLA-A2	NULL
expression	NULL
in	NULL
parental	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
Nef-ER	NULL
#	NULL
2	NULL
,	NULL
despite	NULL
its	NULL
ability	NULL
to	NULL
downmodulate	NULL
CD4	NULL
,	NULL
failed	NULL
to	NULL
downmodulate	NULL
HLA-A2	NULL
to	NULL
a	NULL
significant	NULL
extent	NULL
.	NULL

However	NULL
,	NULL
4-HT	NULL
addition	NULL
to	NULL
Nef-ER	NULL
#	NULL
31	NULL
clone	NULL
did	NULL
lead	NULL
to	NULL
partial	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
in	NULL
24	NULL
h	NULL
,	NULL
which	NULL
was	NULL
increased	NULL
after	NULL
48	NULL
h.	NULL
Comparison	NULL
of	NULL
HLA-A2	NULL
downmodulation	NULL
at	NULL
different	NULL
4-HT	NULL
concentrations	NULL
and	NULL
two	NULL
different	NULL
time	NULL
points	NULL
showed	NULL
that	NULL
50	NULL
%	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
required	NULL
1	NULL
pM	NULL
4-HT	NULL
for	NULL
greater	NULL
than	NULL
16	NULL
h	NULL
or	NULL
100	NULL
nM	NULL
4-HT	NULL
for	NULL
48	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

The	NULL
earliest	NULL
time	NULL
point	NULL
where	NULL
we	NULL
had	NULL
seen	NULL
downmodulation	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
was	NULL
at	NULL
16	NULL
h	NULL
,	NULL
and	NULL
in	NULL
most	NULL
experiments	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
a	NULL
significant	NULL
downmodulation	NULL
until	NULL
24	NULL
h.	NULL
This	NULL
indicated	NULL
that	NULL
the	NULL
Nef-ER-mediated	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
occurs	NULL
more	NULL
slowly	NULL
,	NULL
requiring	NULL
at	NULL
least	NULL
16	NULL
h	NULL
(	NULL
compared	NULL
to	NULL
2	NULL
to	NULL
4	NULL
h	NULL
for	NULL
CD4	NULL
)	NULL
,	NULL
and	NULL
that	NULL
greater	NULL
amounts	NULL
of	NULL
active	NULL
Nef-ER	NULL
molecules	NULL
are	NULL
needed	NULL
(	NULL
based	NULL
on	NULL
the	NULL
50-	NULL
to	NULL
100-fold-higher	NULL
concentrations	NULL
of	NULL
4-HT	NULL
needed	NULL
to	NULL
achieve	NULL
50	NULL
%	NULL
HLA-AZ	NULL
downmodulation	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
even	NULL
at	NULL
the	NULL
higher	NULL
concentrations	NULL
of	NULL
the	NULL
drug	NULL
,	NULL
the	NULL
HLA-A2	NULL
downmodulation	NULL
never	NULL
reached	NULL
the	NULL
maximum	NULL
downmodulation	NULL
seen	NULL
with	NULL
CD4	NULL
.	NULL

We	NULL
consistently	NULL
observed	NULL
HLA-A2	NULL
downmodulation	NULL
only	NULL
in	NULL
Nef-ER	NULL
#	NULL
31	NULL
,	NULL
which	NULL
expresses	NULL
more	NULL
of	NULL
the	NULL
Nef-ER	NULL
protein	NULL
compared	NULL
to	NULL
clone	NULL
Nef-ER	NULL
#	NULL
2	NULL
or	NULL
#	NULL
10	NULL
;	NULL
this	NULL
further	NULL
suggested	NULL
that	NULL
a	NULL
threshold	NULL
level	NULL
of	NULL
active	NULL
Nef	NULL
may	NULL
be	NULL
required	NULL
to	NULL
achieve	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
.	NULL

The	NULL
CD4	NULL
downmodulation	NULL
could	NULL
be	NULL
achieved	NULL
in	NULL
as	NULL
little	NULL
as	NULL
2	NULL
h	NULL
when	NULL
there	NULL
is	NULL
little	NULL
increase	NULL
,	NULL
if	NULL
any	NULL
,	NULL
in	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
,	NULL
while	NULL
HLA-A2	NULL
downmodulation	NULL
occurs	NULL
after	NULL
16	NULL
h	NULL
and	NULL
at	NULL
greater	NULL
than	NULL
10	NULL
nM	NULL
4-HT	NULL
,	NULL
when	NULL
peak	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
are	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

These	NULL
data	NULL
again	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
active	NULL
Nef	NULL
is	NULL
needed	NULL
to	NULL
achieve	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
.	NULL

To	NULL
ensure	NULL
that	NULL
the	NULL
differential	NULL
downmodulation	NULL
of	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
was	NULL
not	NULL
due	NULL
to	NULL
subpopulations	NULL
within	NULL
the	NULL
SupT1	NULL
cells	NULL
being	NULL
analyzed	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
on	NULL
the	NULL
same	NULL
SupT1	NULL
cells	NULL
by	NULL
two-color	NULL
flow	NULL
cytometry	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
under	NULL
conditions	NULL
where	NULL
CD4	NULL
downmodulation	NULL
could	NULL
be	NULL
readily	NULL
detected	NULL
,	NULL
HLA-A2	NULL
downmodulation	NULL
was	NULL
not	NULL
detectable	NULL
on	NULL
these	NULL
cells	NULL
.	NULL

This	NULL
was	NULL
confirmed	NULL
by	NULL
gating	NULL
on	NULL
the	NULL
CD4	NULL
downmodulated	NULL
population	NULL
of	NULL
SupT1	NULL
cells	NULL
and	NULL
comparing	NULL
their	NULL
levels	NULL
of	NULL
HLA-AZ	NULL
surface	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

When	NULL
we	NULL
gated	NULL
on	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
based	NULL
on	NULL
their	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
after	NULL
100	NULL
nM	NULL
4-HT	NULL
treatment	NULL
for	NULL
16	NULL
h	NULL
,	NULL
we	NULL
could	NULL
detect	NULL
CD4	NULL
downmodulation	NULL
on	NULL
all	NULL
the	NULL
cells	NULL
that	NULL
have	NULL
downmodulated	NULL
class	NULL
I	NULL
MHC	NULL
,	NULL
as	NULL
well	NULL
as	NULL
on	NULL
part	NULL
of	NULL
cells	NULL
that	NULL
have	NULL
not	NULL
yet	NULL
downmodulated	NULL
MHC	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
INDUCIBLE	NULL
ACTIVATION	NULL
OF	NULL
HIV-1	NULL
Nef	NULL
FUNCTION	NULL
IN	NULL
T	NULL
CELLS	NULL
839	NULL
A	NULL
Parental	NULL
line	NULL
Nef-ER	NULL
#	NULL
2	NULL
Nef-ER	NULL
#	NULL
31	NULL
8	NULL
,	NULL
B	NULL
§	NULL
d	NULL
a	NULL
o	NULL
4	NULL
3	NULL
g	NULL
1	NULL
£	NULL
€	NULL
.01	NULL
uM	NULL
4-HT	NULL
€	NULL
28	NULL
01	NULL
,	NULL
1	NULL
,	NULL
1	NULL
uM	NULL
4-HT|	NULL
,8	NULL
A	NULL
,	NULL
1	NULL
uM	NULL
4-HT/No	NULL
in	NULL
|	NULL
283	NULL
OLQ	NULL
’	NULL
WM	NULL
4-HT	NULL
3	NULL
&	NULL
3	NULL
3	NULL
38	NULL
ﬁ	NULL
‘	NULL
i	NULL
,	NULL
No	NULL
trt	NULL
.	NULL

|	NULL
38	NULL
\	NULL
j	NULL
38	NULL
$	NULL
``	NULL
D	NULL
5	NULL
a	NULL
g	NULL
£	NULL
%	NULL
§	NULL
¥	NULL
l	NULL
:	NULL
%	NULL
,	NULL
f	NULL
o	NULL
w	NULL
``	NULL
l	NULL
o	NULL
10°	NULL
10	NULL
)	NULL
10°	NULL
10°	NULL
104	NULL
_	NULL
s	NULL
``	NULL
10	NULL
)	NULL
10°	NULL
10°	NULL
s	NULL
<	NULL
Anti-CD4	NULL
Fluorescence	NULL
Intensity	NULL
>	NULL
B	NULL
Nef-ER	NULL
#	NULL
31	NULL
120	NULL
_	NULL
1004	NULL
k	NULL
§	NULL
2	NULL
E€	NULL
\	NULL
s0	NULL
{	NULL
3	NULL
8	NULL
5	NULL
9	NULL
@	NULL
-	NULL
16	NULL
hrs	NULL
of	NULL
4-HT	NULL
g	NULL
601	NULL
®	NULL
$	NULL
~-	NULL
48	NULL
hrs	NULL
of	NULL
4-HT	NULL
$	NULL
5	NULL
LL	NULL
{	NULL
=s	NULL
40	NULL
es	NULL
20	NULL
7	NULL
0	NULL
T	NULL
10	NULL
pM	NULL
_	NULL
100	NULL
pM	NULL
__	NULL
1	NULL
nM	NULL
__	NULL
10	NULL
nM	NULL
_	NULL
100	NULL
nM	NULL
_	NULL
1	NULL
uM	NULL
4-HT	NULL
Concentration	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

4-HT	NULL
dose-dependent	NULL
CD4	NULL
downmodulation	NULL
by	NULL
Nef-ER	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Parental	NULL
SupT1	NULL
or	NULL
Nef-ER	NULL
2	NULL
and	NULL
31	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
,	NULL
100	NULL
nM	NULL
,	NULL
or	NULL
1	NULL
wM	NULL
4-HT	NULL
for	NULL
24	NULL
h	NULL
,	NULL
and	NULL
the	NULL
surface	NULL
level	NULL
of	NULL
CD4	NULL
was	NULL
analyzed	NULL
.	NULL

Data	NULL
from	NULL
10,000	NULL
events	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
are	NULL
shown	NULL
as	NULL
histogram	NULL
along	NULL
with	NULL
the	NULL
background	NULL
staining	NULL
with	NULL
the	NULL
secondary	NULL
antibody	NULL
alone	NULL
(	NULL
solid	NULL
histogram	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
To	NULL
determine	NULL
the	NULL
conditions	NULL
that	NULL
lead	NULL
to	NULL
50	NULL
%	NULL
downmodulation	NULL
of	NULL
cell	NULL
surface	NULL
CD4	NULL
,	NULL
Nef-ER	NULL
31	NULL
was	NULL
treated	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
16	NULL
,	NULL
48	NULL
,	NULL
or	NULL
62	NULL
h	NULL
,	NULL
and	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
was	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
CD4	NULL
MFI	NULL
(	NULL
determined	NULL
using	NULL
the	NULL
CellQuest	NULL
software	NULL
)	NULL
without	NULL
4-HT	NULL
treatment	NULL
was	NULL
set	NULL
as	NULL
100	NULL
%	NULL
,	NULL
and	NULL
MFIs	NULL
at	NULL
the	NULL
different	NULL
conditions	NULL
were	NULL
plotted	NULL
.	NULL

The	NULL
data	NULL
from	NULL
the	NULL
62-h	NULL
points	NULL
were	NULL
essentially	NULL
identical	NULL
to	NULL
the	NULL
data	NULL
at	NULL
the	NULL
48-h	NULL
points	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
50	NULL
%	NULL
downmodulation	NULL
occurred	NULL
at	NULL
2	NULL
nM	NULL
4-HT	NULL
.	NULL

Similar	NULL
experiments	NULL
performed	NULL
with	NULL
clones	NULL
2	NULL
and	NULL
10	NULL
showed	NULL
very	NULL
similar	NULL
results	NULL
except	NULL
that	NULL
the	NULL
50	NULL
%	NULL
downmodulation	NULL
occurred	NULL
at	NULL
~5	NULL
nM	NULL
4-HT	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

DISCUSSION	NULL
We	NULL
report	NULL
here	NULL
the	NULL
design	NULL
and	NULL
use	NULL
of	NULL
a	NULL
regulatable	NULL
Nef-ER	NULL
fusion	NULL
protein	NULL
that	NULL
is	NULL
inducibly	NULL
activated	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
drug	NULL
4-HT	NULL
.	NULL

Stable	NULL
transfectants	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
Nef-ER	NULL
protein	NULL
were	NULL
obtained	NULL
in	NULL
a	NULL
T-cell	NULL
line	NULL
commonly	NULL
used	NULL
in	NULL
HIV-1	NULL
studies	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
drug	NULL
addition	NULL
,	NULL
Nef-ER	NULL
protein	NULL
is	NULL
made	NULL
,	NULL
but	NULL
it	NULL
appears	NULL
to	NULL
be	NULL
completely	NULL
inactive	NULL
for	NULL
several	NULL
of	NULL
the	NULL
known	NULL
functions	NULL
of	NULL
Nef	NULL
.	NULL

The	NULL
inducible	NULL
activation	NULL
of	NULL
Nef-ER	NULL
provides	NULL
a	NULL
unique	NULL
means	NULL
to	NULL
address	NULL
the	NULL
requirements	NULL
for	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
and	NULL
for	NULL
Nef	NULL
activation	NULL
of	NULL
T-cell	NULL
signaling	NULL
pathways	NULL
.	NULL

We	NULL
show	NULL
that	NULL
greater	NULL
protein	NULL
concentrations	NULL
of	NULL
Nef-ER	NULL
are	NULL
needed	NULL
for	NULL
HLA-A2	NULL
downmodulation	NULL
compared	NULL
to	NULL
CD4	NULL
downmodulation	NULL
and	NULL
that	NULL
HLA-A2	NULL
downmodulation	NULL
occurs	NULL
with	NULL
much	NULL
slower	NULL
kinetics	NULL
.	NULL

The	NULL
system	NULL
also	NULL
has	NULL
allowed	NULL
us	NULL
to	NULL
show	NULL
that	NULL
Nef-ER	NULL
associates	NULL
with	NULL
p62	NULL
NAK	NULL
and	NULL
that	NULL
a	NULL
fraction	NULL
of	NULL
Nef-ER	NULL
localizes	NULL
to	NULL
specific	NULL
lipid	NULL
raft	NULL
membrane	NULL
microdomains	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inducibly	NULL
activated	NULL
Nef-ER	NULL
provides	NULL
a	NULL
novel	NULL
and	NULL
readily	NULL
amenable	NULL
means	NULL
for	NULL
expression	NULL
of	NULL
Nef	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Its	NULL
further	NULL
use	NULL
should	NULL
help	NULL
provide	NULL
a	NULL
better	NULL
molecular	NULL
understanding	NULL
of	NULL
Nef	NULL
function	NULL
during	NULL
HIV-1	NULL
infection	NULL
.	NULL

Several	NULL
previous	NULL
studies	NULL
have	NULL
attempted	NULL
expression	NULL
of	NULL
Nef	NULL
in	NULL
T-cell	NULL
lines	NULL
and	NULL
have	NULL
reported	NULL
difficulties	NULL
in	NULL
expressing	NULL
good	NULL
levels	NULL
of	NULL
Nef	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
observe	NULL
that	NULL
the	NULL
stable	NULL
expression	NULL
of	NULL
Nef-ER	NULL
can	NULL
be	NULL
readily	NULL
obtained	NULL
in	NULL
T-cell	NULL
lines	NULL
and	NULL
resultant	NULL
clones	NULL
maintain	NULL
Nef-ER	NULL
expression	NULL
for	NULL
at	NULL
least	NULL
a	NULL
number	NULL
of	NULL
months	NULL
.	NULL

This	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
inactive	NULL
state	NULL
of	NULL
Nef-ER	NULL
until	NULL
4-HT	NULL
is	NULL
added	NULL
,	NULL
apparently	NULL
with	NULL
no	NULL
negative	NULL
selection	NULL
pressure	NULL
in	NULL
cells	NULL
propagated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
drug	NULL
.	NULL

During	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
work	NULL
,	NULL
Trono	NULL
and	NULL
colleagues	NULL
reported	NULL
stable	NULL
expression	NULL
of	NULL
Nef	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
use	NULL
of	NULL
a	NULL
tetracycline-inducible	NULL
system	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Although	NULL
there	NULL
was	NULL
some	NULL
basal	NULL
expression	NULL
,	NULL
this	NULL
provides	NULL
another	NULL
approach	NULL
for	NULL
inducible	NULL
expression	NULL
of	NULL
Nef	NULL
.	NULL

However	NULL
,	NULL
the	NULL
necessity	NULL
to	NULL
generate	NULL
and	NULL
screen	NULL
a	NULL
number	NULL
of	NULL
clones	NULL
for	NULL
tight	NULL
tetracycline-inducible	NULL
expression	NULL
would	NULL
appear	NULL
to	NULL
make	NULL
the	NULL
inducible	NULL
Nef-ER	NULL
an	NULL
easier	NULL
approach	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
Nef-ER	NULL
construct	NULL
can	NULL
readily	NULL
also	NULL
be	NULL
used	NULL
in	NULL
transient	NULL
systems	NULL
,	NULL
with	NULL
Nef	NULL
function	NULL
being	NULL
induced	NULL
when	NULL
desired	NULL
.	NULL

Although	NULL
good	NULL
levels	NULL
of	NULL
Nef-ER	NULL
was	NULL
expressed	NULL
in	NULL
most	NULL
of	NULL
our	NULL
clones	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
4-HT	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
increase	NULL
for	NULL
several	NULL
hours	NULL
after	NULL
4-HT	NULL
addition	NULL
.	NULL

While	NULL
we	NULL
have	NULL
not	NULL
studied	NULL
the	NULL
mechanism	NULL
underlying	NULL
this	NULL
increase	NULL
in	NULL
detail	NULL
,	NULL
the	NULL
use	NULL
of	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
suggests	NULL
that	NULL
4-HT	NULL
inducibly	NULL
activates	NULL
the	NULL
existing	NULL
protein	NULL
.	NULL

It	NULL
840	NULL
WALK	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Parental	NULL
line	NULL
Nef-ER	NULL
#	NULL
2	NULL
J.	NULL
Virou	NULL
.	NULL

Nef-ER	NULL
#	NULL
31	NULL
160	NULL
200	NULL
120	NULL
160	NULL
200	NULL
Counts	NULL
80	NULL
Counts	NULL
80	NULL
-	NULL
120	NULL
40	NULL
40	NULL
0	NULL
Anti-HLA-A2	NULL
Fluorescence	NULL
Intensity	NULL
160	NULL
200	NULL
2	NULL
,	NULL
3	NULL
days	NULL
/	NULL
1	NULL
day	NULL
120	NULL
K1	NULL
,	NULL
2	NULL
,	NULL
3	NULL
days	NULL
Counts	NULL
80	NULL
k	NULL
No	NULL
trt	NULL
.	NULL

40	NULL
B	NULL
Nef-ER	NULL
#	NULL
31	NULL
120	NULL
€	NULL
100	NULL
£	NULL
~	NULL
8	NULL
o	NULL
€€€	NULL
807	NULL
o	NULL
0	NULL
2°	NULL
--	NULL
16	NULL
hrs	NULL
4-HT	NULL
©	NULL
8	NULL
60	NULL
{	NULL
9	NULL
-=-	NULL
48	NULL
hrs	NULL
4-HT	NULL
®	NULL
o	NULL
0	NULL
as	NULL
4	NULL
c	NULL
6	NULL
&	NULL
0	NULL
0°	NULL
25	NULL
20	NULL
0	NULL
l	NULL
T	NULL
Illlllll	NULL
T	NULL
IIIIIIII	NULL
T	NULL
Illlln	NULL
]	NULL
P	NULL
10	NULL
pM	NULL
_	NULL
100	NULL
pM	NULL
1	NULL
nM	NULL
10	NULL
nM	NULL
_	NULL
100	NULL
nM	NULL
_	NULL
1	NULL
uM	NULL
4-HT	NULL
Concentration	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Kinetics	NULL
of	NULL
HLA-A2	NULL
downmodulation	NULL
by	NULL
Nef-ER	NULL
differs	NULL
from	NULL
results	NULL
for	NULL
CD4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Parental	NULL
SupT1	NULL
cells	NULL
or	NULL
the	NULL
Nef-ER-expressing	NULL
clones	NULL
were	NULL
not	NULL
treated	NULL
(	NULL
no	NULL
trt	NULL
.	NULL
)	NULL

or	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
4-HT	NULL
,	NULL
and	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
HLA-A2	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Note	NULL
that	NULL
Nef-ER	NULL
2	NULL
did	NULL
not	NULL
show	NULL
significant	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
even	NULL
at	NULL
3	NULL
days	NULL
in	NULL
this	NULL
experiment	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
conditions	NULL
that	NULL
lead	NULL
to	NULL
50	NULL
%	NULL
HLA-A2	NULL
downmodulation	NULL
were	NULL
assessed	NULL
in	NULL
Nef-ER	NULL
31	NULL
after	NULL
treatment	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
16	NULL
or	NULL
48	NULL
h.	NULL
The	NULL
50	NULL
%	NULL
downmodulation	NULL
occurred	NULL
at	NULL
~90	NULL
nM	NULL
4-HT	NULL
after	NULL
48	NULL
h	NULL
and	NULL
was	NULL
assessed	NULL
as	NULL
described	NULL
for	NULL
CD4	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5B	NULL
.	NULL

seems	NULL
likely	NULL
that	NULL
this	NULL
activation	NULL
also	NULL
stabilizes	NULL
the	NULL
protein	NULL
.	NULL

Thus	NULL
,	NULL
protein	NULL
stabilization	NULL
may	NULL
provide	NULL
a	NULL
fortuitous	NULL
second	NULL
level	NULL
of	NULL
control	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Nef-ER	NULL
function	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
also	NULL
observed	NULL
a	NULL
similar	NULL
increase	NULL
in	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
in	NULL
stably	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
after	NULL
4-HT	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
to	NULL
activate	NULL
Nef-ER	NULL
when	NULL
desired	NULL
allowed	NULL
us	NULL
to	NULL
follow	NULL
the	NULL
time	NULL
course	NULL
of	NULL
downmodulation	NULL
of	NULL
CD4	NULL
and	NULL
HLA-AZ	NULL
.	NULL

Under	NULL
conditions	NULL
when	NULL
Nef-ER	NULL
has	NULL
downmodulated	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
CD4	NULL
,	NULL
no	NULL
detectable	NULL
HLA-A2	NULL
downmodulation	NULL
was	NULL
observed	NULL
.	NULL

While	NULL
we	NULL
could	NULL
detect	NULL
CD4	NULL
downmodulation	NULL
in	NULL
as	NULL
little	NULL
as	NULL
2	NULL
h	NULL
,	NULL
the	NULL
earliest	NULL
time	NULL
point	NULL
where	NULL
we	NULL
had	NULL
seen	NULL
downmodulation	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
was	NULL
at	NULL
16	NULL
h	NULL
,	NULL
and	NULL
in	NULL
most	NULL
experiments	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
a	NULL
significant	NULL
downmodulation	NULL
until	NULL
24	NULL
h.	NULL
Interestingly	NULL
,	NULL
HLA-A2	NULL
downmodulation	NULL
in	NULL
these	NULL
experiments	NULL
required	NULL
20-	NULL
to	NULL
100-fold	NULL
more	NULL
4-HT	NULL
and	NULL
severalfold-higher	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
compared	NULL
to	NULL
comparable	NULL
CD4	NULL
downmodulation	NULL
.	NULL

While	NULL
it	NULL
is	NULL
formally	NULL
possible	NULL
that	NULL
Nef-ER	NULL
may	NULL
be	NULL
activated	NULL
differentially	NULL
in	NULL
an	NULL
artificial	NULL
way	NULL
that	NULL
efficiently	NULL
mediates	NULL
CD4	NULL
downmodulation	NULL
but	NULL
inefficiently	NULL
mediates	NULL
HLA-A2	NULL
downmodulation	NULL
,	NULL
we	NULL
think	NULL
this	NULL
is	NULL
very	NULL
unlikely	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
Nef	NULL
required	NULL
for	NULL
CD4	NULL
downmodulation	NULL
include	NULL
the	NULL
myristoylation	NULL
at	NULL
amino	NULL
acid	NULL
2	NULL
,	NULL
as	NULL
well	NULL
as	NULL
WL	NULL
residues	NULL
around	NULL
position	NULL
58	NULL
and	NULL
the	NULL
two	NULL
leucines	NULL
at	NULL
amino	NULL
acids	NULL
165	NULL
and	NULL
166	NULL
in	NULL
the	NULL
C	NULL
terminus	NULL
(	NULL
47	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HLA-A2	NULL
downmodulation	NULL
requires	NULL
the	NULL
my	NULL
ristoylation	NULL
sequence	NULL
,	NULL
the	NULL
alpha-helical	NULL
structure	NULL
in	NULL
the	NULL
N	NULL
terminus	NULL
,	NULL
the	NULL
acidic	NULL
region	NULL
around	NULL
amino	NULL
acid	NULL
65	NULL
,	NULL
and	NULL
the	NULL
proline-rich	NULL
motifs	NULL
between	NULL
amino	NULL
acids	NULL
69	NULL
and	NULL
81	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
the	NULL
CD4	NULL
downmodulation	NULL
requires	NULL
amino	NULL
acids	NULL
throughout	NULL
the	NULL
protein	NULL
,	NULL
and	NULL
is	NULL
readily	NULL
attained	NULL
by	NULL
Nef-ER	NULL
activation	NULL
,	NULL
HLA-A2	NULL
downmodulation	NULL
requires	NULL
amino	NULL
acids	NULL
at	NULL
the	NULL
N-terminus	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
central	NULL
region	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
simple	NULL
defect	NULL
that	NULL
selectively	NULL
unmasks	NULL
only	NULL
portions	NULL
of	NULL
the	NULL
molecule	NULL
and	NULL
leads	NULL
to	NULL
less	NULL
efficient	NULL
HLA-A2	NULL
downmodulation	NULL
seems	NULL
unlikely	NULL
.	NULL

Nef	NULL
may	NULL
cause	NULL
CD4	NULL
downmodulation	NULL
relatively	NULL
early	NULL
during	NULL
an	NULL
infection	NULL
,	NULL
since	NULL
CD4	NULL
downmodulation	NULL
appears	NULL
to	NULL
require	NULL
a	NULL
very	NULL
small	NULL
amount	NULL
of	NULL
active	NULL
Nef-ER	NULL
and	NULL
occurs	NULL
very	NULL
rapidly	NULL
(	NULL
detectable	NULL
in	NULL
less	NULL
than	NULL
2	NULL
h	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
extent	NULL
of	NULL
Nef-ER-dependent	NULL
CD4	NULL
downmodulation	NULL
reaches	NULL
a	NULL
stable	NULL
equilibrium	NULL
with	NULL
a	NULL
given	NULL
concentration	NULL
of	NULL
4-HT	NULL
,	NULL
and	NULL
this	NULL
did	NULL
not	NULL
increase	NULL
over	NULL
time	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
no	NULL
cumulative	NULL
increase	NULL
in	NULL
active	NULL
Nef-ER	NULL
molecules	NULL
and	NULL
additional	NULL
downmodulation	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
Nef-ER	NULL
protein	NULL
levels	NULL
at	NULL
different	NULL
4-HT	NULL
concentrations	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
CD4	NULL
downmodulation	NULL
appears	NULL
to	NULL
require	NULL
minimal	NULL
amounts	NULL
of	NULL
active	NULL
Nef	NULL
,	NULL
while	NULL
a	NULL
certain	NULL
threshold	NULL
level	NULL
of	NULL
Nef	NULL
must	NULL
be	NULL
reached	NULL
before	NULL
detectable	NULL
HLA-A2	NULL
downmodulation	NULL
occurs	NULL
.	NULL

Precisely	NULL
what	NULL
role	NULL
this	NULL
differential	NULL
timing	NULL
of	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
plays	NULL
in	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
and	NULL
in	NULL
HIV-mediated	NULL
immune	NULL
modulation	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

The	NULL
differential	NULL
kinetics	NULL
and	NULL
amounts	NULL
of	NULL
Nef-ER	NULL
required	NULL
for	NULL
CD4	NULL
downmodulation	NULL
versus	NULL
HLA-A2	NULL
downmodulation	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
INDUCIBLE	NULL
ACTIVATION	NULL
OF	NULL
HIV-1	NULL
Nef	NULL
FUNCTION	NULL
IN	NULL
T	NULL
CELLS	NULL
|	NULL
841	NULL
>	NULL
-*-	NULL
A2	NULL
Dose-response	NULL
~-	NULL
CD4	NULL
Dose-response	NULL
&	NULL
_	NULL
Nef-ER	NULL
#	NULL
31	NULL
c	NULL
o	NULL
120	NULL
QE	NULL
‘	NULL
IOO	NULL
©	NULL
.	NULL

a	NULL
8	NULL
$	NULL
§	NULL
``	NULL
``	NULL
$	NULL
53	NULL
601	NULL
§	NULL
5	NULL
40-LL	NULL
+	NULL
26	NULL
201	NULL
©	NULL
o	NULL
>	NULL
®	NULL
10	NULL
pM	NULL
100	NULL
pM	NULL
1nM	NULL
10	NULL
nM	NULL
100	NULL
nM	NULL
1	NULL
uM	NULL
4-HT	NULL
Concentration	NULL
rad	NULL
M1	NULL
M2	NULL
S	NULL
L_	NULL
a	NULL
]	NULL
4	NULL
10	NULL
nM	NULL
4-HT	NULL
,	NULL
No	NULL
trt	NULL
.	NULL

»	NULL
-	NULL
3	NULL
16	NULL
hrs	NULL
.	NULL

\	NULL
a	NULL
``	NULL
C	NULL
ie	NULL
3	NULL
3	NULL
(	NULL
e	NULL
]	NULL
p	NULL
O	NULL
_	NULL
A	NULL
10°	NULL
10	NULL
!	NULL

-	NULL
10	NULL
10	NULL
%	NULL
10	NULL
%	NULL
Anti-CD4	NULL
Fluorescence	NULL
200	NULL
Counts	NULL
IIIIIIIIII'IIIIIIIIIIlIIl	NULL
©	NULL
<	NULL
D	NULL
0	NULL
10°	NULL
10	NULL
102	NULL
108	NULL
-	NULL
10+	NULL
Anti-HLA-A2	NULL
Fluorescence	NULL
M1	NULL
M2	NULL
A	NULL
9.3	NULL
g-	NULL
C	NULL
N__L	NULL
-	NULL
100	NULL
nM	NULL
4-HT	NULL
,	NULL
No	NULL
trt	NULL
.	NULL

2	NULL
-	NULL
3	NULL
16	NULL
hrs	NULL
.	NULL

3	NULL
3	NULL
O	NULL
4	NULL
O	NULL
-	NULL
7	NULL
0	NULL
3	NULL
102	NULL
108	NULL
Anti-HLA-A2	NULL
Fluorescence	NULL
200	NULL
1	NULL
Counts	NULL
(	NULL
M2	NULL
3	NULL
}	NULL
a	NULL
``	NULL
o	NULL
W	NULL
vond	NULL
10°	NULL
10	NULL
!	NULL

10	NULL
10	NULL
%	NULL
10	NULL
%	NULL
Anti-CD4	NULL
Fluorescence	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Analysis	NULL
of	NULL
CD4	NULL
and	NULL
HLA-A2	NULL
downmodulation	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
by	NULL
two-color	NULL
flow	NULL
cytometry	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nef-ER	NULL
31	NULL
was	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
4-HT	NULL
for	NULL
16	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
double	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-CD4	NULL
and	NULL
PE-conjugated	NULL
anti-HLA-AZ	NULL
antibody	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
two-color	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
MFI	NULL
of	NULL
control	NULL
untreated	NULL
cells	NULL
was	NULL
set	NULL
at	NULL
100	NULL
%	NULL
,	NULL
and	NULL
MFIs	NULL
for	NULL
the	NULL
other	NULL
experimental	NULL
conditions	NULL
were	NULL
plotted	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD4	NULL
expression	NULL
after	NULL
10	NULL
nM	NULL
4-HT	NULL
treatment	NULL
is	NULL
shown	NULL
as	NULL
a	NULL
histogram	NULL
comparing	NULL
it	NULL
with	NULL
CD4	NULL
expression	NULL
on	NULL
untreated	NULL
(	NULL
no	NULL
trt	NULL
.	NULL
)	NULL

cells	NULL
.	NULL

The	NULL
populations	NULL
of	NULL
cells	NULL
with	NULL
normal	NULL
CD4	NULL
(	NULL
M2	NULL
)	NULL
or	NULL
downmodulated	NULL
CD4	NULL
(	NULL
M1	NULL
)	NULL
expression	NULL
were	NULL
gated	NULL
,	NULL
and	NULL
their	NULL
HLA-A2	NULL
expression	NULL
was	NULL
plotted	NULL
.	NULL

Cells	NULL
that	NULL
have	NULL
downmodulated	NULL
CD4	NULL
do	NULL
not	NULL
show	NULL
downmodulation	NULL
of	NULL
HLA-A2	NULL
at	NULL
10	NULL
nM	NULL
4-HT	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Left	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
after	NULL
100	NULL
nM	NULL
treatment	NULL
(	NULL
solid	NULL
histogram	NULL
)	NULL
compared	NULL
to	NULL
that	NULL
for	NULL
untreated	NULL
cells	NULL
;	NULL
right	NULL
,	NULL
CD4	NULL
expression	NULL
on	NULL
4-HT-treated	NULL
cells	NULL
that	NULL
were	NULL
gated	NULL
based	NULL
on	NULL
class	NULL
I	NULL
MHC	NULL
downmodulation	NULL
(	NULL
M1	NULL
versus	NULL
M2	NULL
)	NULL
.	NULL

Downmodulated	NULL
CD4	NULL
is	NULL
detected	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
both	NULL
the	NULL
M1	NULL
and	NULL
M2	NULL
populations	NULL
but	NULL
is	NULL
seen	NULL
more	NULL
readily	NULL
in	NULL
the	NULL
M1	NULL
fraction	NULL
.	NULL

are	NULL
likely	NULL
reflective	NULL
of	NULL
the	NULL
different	NULL
mechanisms	NULL
through	NULL
which	NULL
downmodulation	NULL
occurs	NULL
for	NULL
each	NULL
molecule	NULL
.	NULL

CD4	NULL
downmodulation	NULL
clearly	NULL
involves	NULL
Nef-mediated	NULL
removal	NULL
directly	NULL
from	NULL
the	NULL
cell	NULL
surface	NULL
by	NULL
endocytosis	NULL
through	NULL
linking	NULL
to	NULL
cellular	NULL
adapter	NULL
protein	NULL
complexes	NULL
such	NULL
as	NULL
AP-1	NULL
,	NULL
AP-2	NULL
,	NULL
and/or	NULL
AP-3	NULL
(	NULL
18	NULL
,	NULL
46-48	NULL
)	NULL
.	NULL

However	NULL
,	NULL
multiple	NULL
mechanisms	NULL
of	NULL
HLA-A2	NULL
downmodulation	NULL
have	NULL
been	NULL
implicated	NULL
.	NULL

The	NULL
original	NULL
report	NULL
by	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

suggested	NULL
an	NULL
increased	NULL
rate	NULL
of	NULL
endocytosis	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
842	NULL
WALK	NULL
ET	NULL
AL	NULL
.	NULL

mediated	NULL
by	NULL
Nef	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Greenberg	NULL
et	NULL
al	NULL
.	NULL

showed	NULL
that	NULL
Nef	NULL
causes	NULL
accumulation	NULL
of	NULL
endocytosed	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
along	NULL
with	NULL
AP-2	NULL
in	NULL
the	NULL
trans-Golgi	NULL
network	NULL
in	NULL
fibroblasts	NULL
(	NULL
19	NULL
)	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
has	NULL
suggested	NULL
that	NULL
Nef	NULL
acts	NULL
as	NULL
a	NULL
connector	NULL
between	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
surface	NULL
HLA	NULL
molecules	NULL
and	NULL
the	NULL
PACS-1-dependent	NULL
protein	NULL
sorting	NULL
pathway	NULL
,	NULL
to	NULL
target	NULL
HLA	NULL
molecules	NULL
to	NULL
the	NULL
trans-Golgi	NULL
network	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
downmodulation	NULL
by	NULL
Nef	NULL
involves	NULL
a	NULL
block	NULL
in	NULL
transport	NULL
of	NULL
newly	NULL
synthesized	NULL
HLA	NULL
molecules	NULL
to	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
causing	NULL
them	NULL
to	NULL
accumulate	NULL
in	NULL
the	NULL
Golgi	NULL
apparatus	NULL
(	NULL
K.	NULL
L.	NULL
Collins	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
basal	NULL
MHC	NULL
class	NULL
I	NULL
recycling	NULL
from	NULL
the	NULL
cell	NULL
surface	NULL
appears	NULL
to	NULL
be	NULL
cell	NULL
type	NULL
dependent	NULL
and	NULL
may	NULL
also	NULL
affect	NULL
the	NULL
Nef-mediated	NULL
downmodulation	NULL
(	NULL
19	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
recent	NULL
report	NULL
suggests	NULL
that	NULL
Nef	NULL
affects	NULL
endocytosis	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
is	NULL
distinct	NULL
or	NULL
at	NULL
least	NULL
additive	NULL
to	NULL
the	NULL
prototypic	NULL
endocytosis	NULL
mechanisms	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Clearly	NULL
,	NULL
downmodulation	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
by	NULL
any	NULL
of	NULL
these	NULL
mechanisms	NULL
could	NULL
require	NULL
different	NULL
amounts	NULL
of	NULL
Nef	NULL
compared	NULL
to	NULL
the	NULL
CD4	NULL
endocytosis	NULL
and	NULL
provide	NULL
a	NULL
possible	NULL
explanation	NULL
for	NULL
our	NULL
results	NULL
.	NULL

Recently	NULL
,	NULL
specific	NULL
membrane	NULL
microdomains	NULL
known	NULL
as	NULL
lipid	NULL
rafts	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
many	NULL
other	NULL
cell	NULL
types	NULL
(	NULL
7	NULL
,	NULL
25	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
localization	NULL
of	NULL
a	NULL
portion	NULL
of	NULL
Nef	NULL
to	NULL
lipid	NULL
rafts	NULL
provides	NULL
the	NULL
intriguing	NULL
possibility	NULL
that	NULL
this	NULL
may	NULL
be	NULL
an	NULL
important	NULL
aspect	NULL
for	NULL
mediating	NULL
Nef	NULL
's	NULL
ef-fects	NULL
.	NULL

We	NULL
observe	NULL
that	NULL
Nef-ER	NULL
localization	NULL
to	NULL
the	NULL
lipid	NULL
rafts	NULL
occurs	NULL
only	NULL
after	NULL
4-HT	NULL
addition	NULL
and	NULL
that	NULL
it	NULL
temporally	NULL
correlates	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
Nef-ER	NULL
to	NULL
modulate	NULL
CD4	NULL
downmodulation	NULL
and	NULL
p62	NULL
NAK	NULL
binding	NULL
.	NULL

The	NULL
ER	NULL
fusion	NULL
is	NULL
at	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
Nef	NULL
while	NULL
the	NULL
myristoylation	NULL
required	NULL
for	NULL
Nef	NULL
raft	NULL
localization	NULL
is	NULL
at	NULL
the	NULL
very	NULL
N	NULL
terminus	NULL
of	NULL
Nef	NULL
,	NULL
which	NULL
suggests	NULL
a	NULL
significant	NULL
steric	NULL
hindrance	NULL
of	NULL
the	NULL
entire	NULL
Nef	NULL
region	NULL
in	NULL
the	NULL
Nef-ER	NULL
fusion	NULL
protein	NULL
.	NULL

During	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
report	NULL
,	NULL
Trono	NULL
and	NULL
colleagues	NULL
have	NULL
also	NULL
reported	NULL
the	NULL
localization	NULL
of	NULL
Nef	NULL
to	NULL
the	NULL
lipid	NULL
rafts	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Although	NULL
only	NULL
a	NULL
small	NULL
fraction	NULL
of	NULL
Nef	NULL
was	NULL
seen	NULL
in	NULL
the	NULL
raft	NULL
fraction	NULL
compared	NULL
to	NULL
the	NULL
nonraft	NULL
fraction	NULL
by	NULL
us	NULL
and	NULL
by	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
65	NULL
)	NULL
,	NULL
it	NULL
could	NULL
represent	NULL
the	NULL
functional	NULL
pool	NULL
of	NULL
Nef	NULL
in	NULL
the	NULL
cells	NULL
.	NULL

It	NULL
has	NULL
been	NULL
seen	NULL
with	NULL
other	NULL
signaling	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
Shc	NULL
,	NULL
that	NULL
the	NULL
3	NULL
to	NULL
5	NULL
%	NULL
of	NULL
total	NULL
cellular	NULL
She	NULL
protein	NULL
that	NULL
is	NULL
localized	NULL
to	NULL
the	NULL
membrane	NULL
represents	NULL
the	NULL
functional	NULL
pool	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Since	NULL
a	NULL
major	NULL
fraction	NULL
of	NULL
dually	NULL
acylated	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
the	NULL
Sre	NULL
family	NULL
kinase	NULL
Lck	NULL
,	NULL
are	NULL
found	NULL
in	NULL
the	NULL
rafts	NULL
(	NULL
7	NULL
,	NULL
10	NULL
)	NULL
,	NULL
it	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
whether	NULL
Nef	NULL
localization	NULL
to	NULL
the	NULL
rafts	NULL
is	NULL
necessary	NULL
to	NULL
target	NULL
the	NULL
CD4-Lck	NULL
complex	NULL
for	NULL
downmodulation	NULL
.	NULL

It	NULL
is	NULL
also	NULL
intriguing	NULL
that	NULL
linker	NULL
for	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
LAT	NULL
)	NULL
(	NULL
which	NULL
is	NULL
also	NULL
dually	NULL
acylated	NULL
and	NULL
is	NULL
constitutively	NULL
found	NULL
in	NULL
the	NULL
rafts	NULL
)	NULL
(	NULL
37	NULL
,	NULL
68	NULL
)	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
hyperphosphorylated	NULL
in	NULL
thymocytes	NULL
of	NULL
mice	NULL
expressing	NULL
Nef	NULL
as	NULL
a	NULL
transgene	NULL
(	NULL
21	NULL
)	NULL
.	NULL

While	NULL
these	NULL
data	NULL
provide	NULL
an	NULL
intriguing	NULL
correlation	NULL
,	NULL
experiments	NULL
that	NULL
directly	NULL
target	NULL
Nef	NULL
to	NULL
these	NULL
lipid	NULL
rafts	NULL
or	NULL
specifically	NULL
disrupt	NULL
Nef	NULL
from	NULL
these	NULL
rafts	NULL
are	NULL
needed	NULL
to	NULL
determine	NULL
the	NULL
precise	NULL
role	NULL
of	NULL
this	NULL
localization	NULL
.	NULL

The	NULL
precise	NULL
interaction	NULL
between	NULL
Nef	NULL
and	NULL
the	NULL
PAK	NULL
family	NULL
kinase	NULL
has	NULL
been	NULL
difficult	NULL
to	NULL
address	NULL
due	NULL
to	NULL
expression	NULL
problems	NULL
with	NULL
Nef	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
NAK	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
PAK1	NULL
or	NULL
PAK2	NULL
by	NULL
two	NULL
different	NULL
groups	NULL
(	NULL
16	NULL
,	NULL
52	NULL
)	NULL
,	NULL
the	NULL
precise	NULL
PAK	NULL
family	NULL
member	NULL
that	NULL
binds	NULL
to	NULL
Nef	NULL
in	NULL
T	NULL
cells	NULL
has	NULL
not	NULL
been	NULL
determined	NULL
.	NULL

Moreover	NULL
,	NULL
some	NULL
experiments	NULL
have	NULL
indicated	NULL
that	NULL
another	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
PXXP	NULL
motifs	NULL
in	NULL
Nef	NULL
may	NULL
facilitate	NULL
PAK-Nef	NULL
binding	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
inducible	NULL
association	NULL
of	NULL
Nef-ER	NULL
with	NULL
the	NULL
PAK	NULL
family	NULL
kinase	NULL
in	NULL
a	NULL
homogeneous	NULL
popu-	NULL
J.	NULL
Virou	NULL
.	NULL

lation	NULL
of	NULL
T	NULL
cells	NULL
may	NULL
help	NULL
in	NULL
delineating	NULL
the	NULL
Nef-PAK	NULL
binding	NULL
and	NULL
subsequent	NULL
regulation	NULL
.	NULL

Myriad	NULL
interaction	NULL
partners	NULL
and	NULL
putative	NULL
roles	NULL
for	NULL
Nef	NULL
have	NULL
been	NULL
proposed	NULL
based	NULL
on	NULL
studies	NULL
with	NULL
Nef	NULL
(	NULL
42	NULL
)	NULL
,	NULL
often	NULL
performed	NULL
in	NULL
non-T-cell	NULL
lines	NULL
,	NULL
due	NULL
to	NULL
ease	NULL
of	NULL
Nef	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
and	NULL
the	NULL
difficulties	NULL
of	NULL
expression	NULL
in	NULL
T-cell	NULL
lines	NULL
.	NULL

Which	NULL
of	NULL
these	NULL
interactions	NULL
are	NULL
relevant	NULL
in	NULL
the	NULL
natural	NULL
cell	NULL
types	NULL
that	NULL
HIV	NULL
infects	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
difficulties	NULL
in	NULL
Nef	NULL
expression	NULL
in	NULL
T-cell	NULL
lines	NULL
may	NULL
have	NULL
prevented	NULL
the	NULL
identification	NULL
of	NULL
Nef-interacting	NULL
partners	NULL
and	NULL
Nef	NULL
function	NULL
that	NULL
may	NULL
be	NULL
unique	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
Nef-ER	NULL
described	NULL
here	NULL
may	NULL
prove	NULL
useful	NULL
in	NULL
addressing	NULL
at	NULL
least	NULL
some	NULL
of	NULL
these	NULL
unanswered	NULL
questions	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grant	NULL
R21-AI44349	NULL
and	NULL
by	NULL
the	NULL
Charles	NULL
H.	NULL
Ross	NULL
Jr.	NULL
and	NULL
Myles	NULL
H.	NULL
Thaler	NULL
endowments	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Virginia	NULL
.	NULL

We	NULL
thank	NULL
the	NULL
Beirne	NULL
Carter	NULL
Foundation	NULL
for	NULL
continued	NULL
support	NULL
.	NULL

We	NULL
thank	NULL
Javad	NULL
Aman	NULL
for	NULL
help	NULL
with	NULL
the	NULL
raft	NULL
experiments	NULL
and	NULL
other	NULL
members	NULL
of	NULL
the	NULL
Ravichandran	NULL
laboratory	NULL
for	NULL
helpful	NULL
suggestions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Aiken	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Konner	NULL
,	NULL
N.	NULL
R.	NULL
Landau	NULL
,	NULL
M.	NULL
E.	NULL
Lenburg	NULL
,	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

1994	NULL
.	NULL

Nef	NULL
induces	NULL
CD4	NULL
endocytosis	NULL
:	NULL
requirement	NULL
for	NULL
a	NULL
critical	NULL
dileucine	NULL
motif	NULL
in	NULL
the	NULL
membrane-proximal	NULL
CD4	NULL
cytoplasmic	NULL
domain	NULL
.	NULL

Cell	NULL
76:853-864	NULL
.	NULL

2	NULL
.	NULL

Aiken	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
Tromo	NULL
.	NULL

1995	NULL
.	NULL

Nef	NULL
stimulates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
proviral	NULL
DNA	NULL
synthesis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:5048-5056	NULL
.	NULL

3	NULL
.	NULL

Aman	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
K.	NULL
S.	NULL
Ravichandran	NULL
,	NULL
2000	NULL
.	NULL

A	NULL
requirement	NULL
for	NULL
lipid	NULL
rafts	NULL
in	NULL
B	NULL
cell	NULL
receptor	NULL
induced	NULL
Ca**	NULL
flux	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

10:393-396	NULL
.	NULL

4	NULL
.	NULL

Baur	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
G.	NULL
Sass	NULL
,	NULL
B.	NULL
Laffert	NULL
,	NULL
D.	NULL
Willbold	NULL
,	NULL
C.	NULL
Cheng-Mayer	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
N-terminus	NULL
of	NULL
Nef	NULL
from	NULL
HIV-1/SIV	NULL
associates	NULL
with	NULL
a	NULL
protein	NULL
complex	NULL
containing	NULL
Leck	NULL
and	NULL
a	NULL
serine	NULL
kinase	NULL
.	NULL

Immunity	NULL
6:283-291	NULL
.	NULL

5	NULL
.	NULL

Baur	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
E.	NULL
T.	NULL
Sawai	NULL
,	NULL
P.	NULL
Dazin	NULL
,	NULL
W.	NULL
J.	NULL
Fantl	NULL
,	NULL
C.	NULL
Cheng-Mayer	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1994	NULL
.	NULL

HIV-1	NULL
Nef	NULL
leads	NULL
to	NULL
inhibition	NULL
or	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
depending	NULL
on	NULL
its	NULL
intracellular	NULL
localization	NULL
.	NULL

Immunity	NULL
1:373-384	NULL
.	NULL

6	NULL
.	NULL

Brown	NULL
,	NULL
A.	NULL
,	NULL
X.	NULL
Wang	NULL
,	NULL
E.	NULL
Sawai	NULL
,	NULL
and	NULL
C.	NULL
Cheng-Mayer	NULL
.	NULL

1999	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
PAK-related	NULL
kinase	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Nef	NULL
in	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
leads	NULL
to	NULL
phosphor-ylation	NULL
of	NULL
a	NULL
PIX-p95	NULL
complex	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:9899-9907	NULL
.	NULL

7	NULL
.	NULL

Brown	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
London	NULL
.	NULL

1998	NULL
.	NULL

Functions	NULL
of	NULL
lipid	NULL
rafts	NULL
in	NULL
biological	NULL
membranes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Dev	NULL
.	NULL

Biol	NULL
.	NULL

14:111-136	NULL
.	NULL

8	NULL
.	NULL

Carl	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
J.	NULL
Iafrate	NULL
,	NULL
S.	NULL
M.	NULL
Lang	NULL
,	NULL
N.	NULL
Stolte	NULL
,	NULL
C.	NULL
Stahl-Hennig	NULL
,	NULL
K.	NULL
Matz-Rensing	NULL
,	NULL
D.	NULL
Fuchs	NULL
,	NULL
J.	NULL
Skowronski	NULL
,	NULL
and	NULL
F.	NULL
Kirchhoff	NULL
.	NULL

2000	NULL
.	NULL

Simian	NULL
immunodeficiency	NULL
virus	NULL
containing	NULL
mutations	NULL
in	NULL
N-terminal	NULL
tyrosine	NULL
residues	NULL
and	NULL
in	NULL
the	NULL
PxxP	NULL
motif	NULL
in	NULL
Nef	NULL
replicates	NULL
efficiently	NULL
in	NULL
rhesus	NULL
macaques	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

74	NULL
:	NULL
4155-4164	NULL
.	NULL

9	NULL
.	NULL

Carver	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Aman	NULL
,	NULL
and	NULL
K.	NULL
Ravichandran	NULL
,	NULL
.	NULL

2000	NULL
.	NULL

SHIP	NULL
inhibits	NULL
Akt	NULL
activation	NULL
in	NULL
B	NULL
cells	NULL
through	NULL
regulation	NULL
of	NULL
Akt	NULL
membrane	NULL
localization	NULL
.	NULL

Blood	NULL
96	NULL
:	NULL
1449-1456	NULL
.	NULL

10	NULL
.	NULL

Cary	NULL
,	NULL
L	NULL
A.	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Cooper	NULL
,	NULL
2000	NULL
.	NULL

Molecular	NULL
switches	NULL
in	NULL
lipid	NULL
rafts	NULL
.	NULL

Nature	NULL
404:945	NULL
,	NULL
947	NULL
.	NULL

11	NULL
.	NULL

Chowers	NULL
,	NULL
M.	NULL
Y.	NULL
,	NULL
C.	NULL
A.	NULL
Spina	NULL
,	NULL
T.	NULL
J.	NULL
Kwoh	NULL
,	NULL
N.	NULL
J.	NULL
Fitch	NULL
,	NULL
D.	NULL
D.	NULL
Richman	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Guatelli	NULL
.	NULL

1994	NULL
.	NULL

Optimal	NULL
infectivity	NULL
in	NULL
vitro	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
requires	NULL
an	NULL
intact	NULL
nef	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2906-2914	NULL
.	NULL

12	NULL
.	NULL

Cohen	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
R.	NULL
T.	NULL
Gandhi	NULL
,	NULL
D.	NULL
M.	NULL
Davis	NULL
,	NULL
O.	NULL
Mandelboim	NULL
,	NULL
B.	NULL
K.	NULL
Chen	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
selective	NULL
downregulation	NULL
of	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex	NULL
proteins	NULL
by	NULL
HIV-1	NULL
protects	NULL
HIV-infected	NULL
cells	NULL
from	NULL
NK	NULL
cells	NULL
.	NULL

Immunity	NULL
10:661-671	NULL
.	NULL

13	NULL
.	NULL

Collins	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1999	NULL
.	NULL

HIV	NULL
's	NULL
evasion	NULL
of	NULL
the	NULL
cellular	NULL
immune	NULL
response	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

168:65-74	NULL
.	NULL

14	NULL
.	NULL

Collins	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
B.	NULL
K.	NULL
Chen	NULL
,	NULL
S.	NULL
A.	NULL
Kalams	NULL
,	NULL
B.	NULL
D.	NULL
Walker	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1998	NULL
.	NULL

HIV-1	NULL
Nef	NULL
protein	NULL
protects	NULL
infected	NULL
primary	NULL
cells	NULL
against	NULL
killing	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
391:397-401	NULL
.	NULL

15	NULL
.	NULL

Deacon	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
A.	NULL
Tsykin	NULL
,	NULL
A.	NULL
Solomon	NULL
,	NULL
K.	NULL
Smith	NULL
,	NULL
M.	NULL
Ludford-Menting	NULL
,	NULL
D.	NULL
J.	NULL
Hooker	NULL
,	NULL
D.	NULL
A.	NULL
McPhee	NULL
,	NULL
A.	NULL
L.	NULL
Greenway	NULL
,	NULL
A.	NULL
Ellett	NULL
,	NULL
C.	NULL
Chatfield	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Genomic	NULL
structure	NULL
of	NULL
an	NULL
attenuated	NULL
quasi	NULL
species	NULL
of	NULL
HIV-1	NULL
from	NULL
a	NULL
blood	NULL
transfusion	NULL
donor	NULL
and	NULL
recipients	NULL
.	NULL

Science	NULL
270:988-991	NULL
.	NULL

16	NULL
.	NULL

Fackler	NULL
,	NULL
O.	NULL
T.	NULL
,	NULL
X.	NULL
Lu	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Frost	NULL
,	NULL
M.	NULL
Geyer	NULL
,	NULL
B.	NULL
Jiang	NULL
,	NULL
W.	NULL
Luo	NULL
,	NULL
A.	NULL
Abo	NULL
,	NULL
A.	NULL
S.	NULL
Alberts	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

2000.	NULL
p21-activated	NULL
kinase	NULL
1	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
cellular	NULL
activation	NULL
by	NULL
Nef	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

20:2619-2627	NULL
.	NULL

17	NULL
.	NULL

Garcia	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Miller	NULL
.	NULL

1991	NULL
.	NULL

Serine	NULL
phosphorylation-independent	NULL
downregulation	NULL
of	NULL
cell-surface	NULL
CD4	NULL
by	NULL
nef	NULL
.	NULL

Nature	NULL
350:508-511	NULL
.	NULL

18	NULL
.	NULL

Greenberg	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
DeTulleo	NULL
,	NULL
I.	NULL
Rapoport	NULL
,	NULL
J.	NULL
Skowronski	NULL
,	NULL
and	NULL
T.	NULL
Kirch-hausen	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
dileucine	NULL
motif	NULL
in	NULL
HIV-1	NULL
Nef	NULL
is	NULL
essential	NULL
for	NULL
sorting	NULL
into	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42.	NULL
clathrin-coated	NULL
pits	NULL
and	NULL
for	NULL
downregulation	NULL
of	NULL
CD4	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

8:1239-1242	NULL
.	NULL

Greenberg	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
A.	NULL
J.	NULL
Iafrate	NULL
,	NULL
and	NULL
J.	NULL
Skowronski	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
SH3	NULL
domain-binding	NULL
surface	NULL
and	NULL
an	NULL
acidic	NULL
motif	NULL
in	NULL
HIV-1	NULL
Nef	NULL
regulate	NULL
trafficking	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
complexes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

17:2777-2789	NULL
.	NULL

Guy	NULL
,	NULL
B.	NULL
,	NULL
M.	NULL
P.	NULL
Kieny	NULL
,	NULL
Y.	NULL
Riviere	NULL
,	NULL
C.	NULL
Le	NULL
Peuch	NULL
,	NULL
K.	NULL
Dott	NULL
,	NULL
M.	NULL
Girard	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Lecocq	NULL
.	NULL

1987	NULL
.	NULL

HIV	NULL
F/3	NULL
'	NULL
orf	NULL
encodes	NULL
a	NULL
phosphorylated	NULL
GTP-binding	NULL
protein	NULL
resembling	NULL
an	NULL
oncogene	NULL
product	NULL
.	NULL

Nature	NULL
330:266-269	NULL
.	NULL

Hanna	NULL
,	NULL
Z.	NULL
,	NULL
D.	NULL
G.	NULL
Kay	NULL
,	NULL
N.	NULL
Rebai	NULL
,	NULL
A.	NULL
Guimond	NULL
,	NULL
S.	NULL
Jothy	NULL
,	NULL
and	NULL
P.	NULL
Jolicoeur	NULL
.	NULL

1998	NULL
.	NULL

Nef	NULL
harbors	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
pathogenicity	NULL
for	NULL
an	NULL
AIDS-like	NULL
disease	NULL
induced	NULL
by	NULL
HIV-1	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Cell	NULL
95:163-175	NULL
.	NULL

Harris	NULL
,	NULL
M.	NULL
1995	NULL
.	NULL

The	NULL
role	NULL
of	NULL
myristoylation	NULL
in	NULL
the	NULL
interactions	NULL
between	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
I	NULL
Nef	NULL
and	NULL
cellular	NULL
proteins	NULL
.	NULL

Biochem	NULL
.	NULL

Soc	NULL
.	NULL

Trans	NULL
.	NULL

23:557-561	NULL
.	NULL

Iafrate	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
S.	NULL
Bronson	NULL
,	NULL
and	NULL
J.	NULL
Skowronski	NULL
.	NULL

1997	NULL
.	NULL

Separable	NULL
functions	NULL
of	NULL
Nef	NULL
disrupt	NULL
two	NULL
aspects	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
machinery	NULL
:	NULL
CD4	NULL
expression	NULL
and	NULL
CD3	NULL
signaling	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:673-684	NULL
.	NULL

Janes	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
S.	NULL
C.	NULL
Ley	NULL
,	NULL
and	NULL
A.	NULL
I.	NULL
Magee	NULL
.	NULL

1999	NULL
.	NULL

Aggregation	NULL
of	NULL
lipid	NULL
rafts	NULL
accompanies	NULL
signaling	NULL
via	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

147:447-461	NULL
.	NULL

Janes	NULL
,	NULL
P.	NULL
W.	NULL
,	NULL
S.	NULL
C.	NULL
Ley	NULL
,	NULL
A.	NULL
I.	NULL
Magee	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Kabouridis	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
role	NULL
of	NULL
lipid	NULL
rafts	NULL
in	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
signalling	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

1223-34	NULL
.	NULL

Kaminchik	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
Bashan	NULL
,	NULL
A.	NULL
Itach	NULL
,	NULL
N.	NULL
Sarver	NULL
,	NULL
M.	NULL
Gorecki	NULL
,	NULL
and	NULL
A.	NULL
Panet	NULL
.	NULL

1991	NULL
.	NULL

Genetic	NULL
characterization	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
nef	NULL
gene	NULL
products	NULL
translated	NULL
in	NULL
vitro	NULL
and	NULL
expressed	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:583-588	NULL
.	NULL

Kestler	NULL
,	NULL
H.	NULL
W.	NULL
D.	NULL
,	NULL
D.	NULL
J.	NULL
Ringler	NULL
,	NULL
K.	NULL
Mori	NULL
,	NULL
D.	NULL
L.	NULL
Panicali	NULL
,	NULL
P.	NULL
K.	NULL
Sehgal	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1991	NULL
.	NULL

Importance	NULL
of	NULL
the	NULL
nef	NULL
gene	NULL
for	NULL
maintenance	NULL
of	NULL
high	NULL
virus	NULL
loads	NULL
and	NULL
for	NULL
development	NULL
of	NULL
AIDS	NULL
.	NULL

Cell	NULL
65:651-662	NULL
.	NULL

Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
J.	NULL
Easterbrook	NULL
,	NULL
N.	NULL
Douglas	NULL
,	NULL
M.	NULL
Troop	NULL
,	NULL
T.	NULL
C.	NULL
Greenough	NULL
,	NULL
J.	NULL
Weber	NULL
,	NULL
S.	NULL
Carl	NULL
,	NULL
J.	NULL
L.	NULL
Sullivan	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Daniels	NULL
.	NULL

1999	NULL
.	NULL

Sequence	NULL
variations	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Nef	NULL
are	NULL
associated	NULL
with	NULL
different	NULL
stages	NULL
of	NULL
disease	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:5497-5508	NULL
.	NULL

Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
T.	NULL
C.	NULL
Greenough	NULL
,	NULL
D.	NULL
B.	NULL
Brettler	NULL
,	NULL
J.	NULL
L.	NULL
Sullivan	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1995	NULL
.	NULL

Brief	NULL
report	NULL
:	NULL
absence	NULL
of	NULL
intact	NULL
nef	NULL
sequences	NULL
in	NULL
a	NULL
long-term	NULL
survivor	NULL
with	NULL
nonprogressive	NULL
HIV-1	NULL
infection	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

332:228-232	NULL
.	NULL

Klippel	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Escobedo	NULL
,	NULL
M.	NULL
S.	NULL
Wachowicz	NULL
,	NULL
G.	NULL
Apell	NULL
,	NULL
T.	NULL
W.	NULL
Brown	NULL
,	NULL
M.	NULL
A.	NULL
Giedlin	NULL
,	NULL
W.	NULL
M.	NULL
Kavanaugh	NULL
,	NULL
and	NULL
L.	NULL
T.	NULL
Williams	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
phos-phatidylinositol	NULL
3-kinase	NULL
is	NULL
sufficient	NULL
for	NULL
cell	NULL
cycle	NULL
entry	NULL
and	NULL
promotes	NULL
cellular	NULL
changes	NULL
characteristic	NULL
of	NULL
oncogenic	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
:	NULL
5699-5711	NULL
.	NULL

Kohn	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
A.	NULL
Barthel	NULL
,	NULL
K.	NULL
S.	NULL
Kovacina	NULL
,	NULL
A.	NULL
Boge	NULL
,	NULL
B.	NULL
Wallach	NULL
,	NULL
S.	NULL
A.	NULL
Summers	NULL
,	NULL
M.	NULL
J.	NULL
Birnbaum	NULL
,	NULL
P.	NULL
H.	NULL
Scott	NULL
,	NULL
J.	NULL
C.	NULL
Lawrence	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Roth	NULL
.	NULL

1998	NULL
.	NULL

Construction	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
conditionally	NULL
active	NULL
version	NULL
of	NULL
the	NULL
serine/threonine	NULL
kinase	NULL
Akt	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:11937-11943	NULL
.	NULL

Lamkin	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
S.	NULL
F.	NULL
Walk	NULL
,	NULL
L.	NULL
Liu	NULL
,	NULL
J.	NULL
E.	NULL
Damen	NULL
,	NULL
G.	NULL
Krystal	NULL
,	NULL
and	NULL
K.	NULL
S.	NULL
Ravichandran	NULL
,	NULL
.	NULL

1997	NULL
.	NULL

Shc	NULL
interaction	NULL
with	NULL
Src	NULL
homology	NULL
2	NULL
domain	NULL
containing	NULL
inositol	NULL
phosphatase	NULL
(	NULL
SHIP	NULL
)	NULL
in	NULL
vivo	NULL
requires	NULL
the	NULL
Shc-phosphotyrosine	NULL
binding	NULL
domain	NULL
and	NULL
two	NULL
specific	NULL
phosphotyrosines	NULL
on	NULL
SHIP	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
;	NULL
10396-10401	NULL
.	NULL

Lang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
A.	NULL
J.	NULL
Iafrate	NULL
,	NULL
C.	NULL
Stahl-Hennig	NULL
,	NULL
E.	NULL
M.	NULL
Kubn	NULL
,	NULL
T.	NULL
Nisslein	NULL
,	NULL
F.	NULL
J.	NULL
Kaup	NULL
,	NULL
M.	NULL
Haupt	NULL
,	NULL
G.	NULL
Hunsmann	NULL
,	NULL
J.	NULL
Skowronski	NULL
,	NULL
and	NULL
F.	NULL
Kirchhoff	NULL
.	NULL

1997	NULL
.	NULL

Association	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
Nef	NULL
with	NULL
cellular	NULL
serine/threonine	NULL
kinases	NULL
is	NULL
dispensable	NULL
for	NULL
the	NULL
development	NULL
of	NULL
AIDS	NULL
in	NULL
rhesus	NULL
macaques	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

3:860-865	NULL
.	NULL

Langlet	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
M.	NULL
Bernard	NULL
,	NULL
P.	NULL
Drevot	NULL
,	NULL
and	NULL
H.	NULL
T.	NULL
He	NULL
.	NULL

2000	NULL
.	NULL

Membrane	NULL
rafts	NULL
and	NULL
signaling	NULL
by	NULL
the	NULL
multichain	NULL
immune	NULL
recognition	NULL
receptors	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

12:250-255	NULL
.	NULL

Le	NULL
Gall	NULL
,	NULL
S.	NULL
,	NULL
F.	NULL
Buseyne	NULL
,	NULL
A.	NULL
Trocha	NULL
,	NULL
B.	NULL
D.	NULL
Walker	NULL
,	NULL
J.	NULL
M.	NULL
Heard	NULL
,	NULL
and	NULL
O.	NULL
Schwartz	NULL
.	NULL

2000	NULL
.	NULL

Distinct	NULL
trafficking	NULL
pathways	NULL
mediate	NULL
Nef-induced	NULL
and	NULL
clath-rin-dependent	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
down-regulation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

74:9256-9266	NULL
.	NULL

Le	NULL
Gall	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
C.	NULL
Prevost	NULL
,	NULL
J.	NULL
M.	NULL
Heard	NULL
,	NULL
and	NULL
O.	NULL
Schwartz	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
I	NULL
Nef	NULL
independently	NULL
affects	NULL
virion	NULL
incorporation	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
molecules	NULL
and	NULL
virus	NULL
infectivity	NULL
.	NULL

Virology	NULL
229:295-301	NULL
.	NULL

Lin	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Finco	NULL
.	NULL

1999	NULL
.	NULL

Localization	NULL
of	NULL
LAT	NULL
in	NULL
glycolipid-enriched	NULL
microdomains	NULL
is	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
:	NULL
28861-28864	NULL
.	NULL

Lucchiari	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
Niedermann	NULL
,	NULL
C.	NULL
Leipner	NULL
,	NULL
A.	NULL
Meyerhans	NULL
,	NULL
K.	NULL
Eichmann	NULL
,	NULL
and	NULL
B.	NULL
Maier	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immune	NULL
response	NULL
to	NULL
HIV-1-Nef	NULL
.	NULL

I.	NULL
CD45RO-	NULL
T	NULL
lymphocytes	NULL
of	NULL
non-infected	NULL
donors	NULL
contain	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
precursors	NULL
at	NULL
high	NULL
frequency	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

61739-1749	NULL
.	NULL

Manninen	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Herma	NULL
Renkema	NULL
,	NULL
and	NULL
K.	NULL
Saksela	NULL
.	NULL

2000	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
HIV-1	NULL
nef	NULL
and	NULL
the	NULL
Ras/MAPK	NULL
pathway	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

275:16513-16517	NULL
.	NULL

Manninen	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Hiipakka	NULL
,	NULL
M.	NULL
Vihinen	NULL
,	NULL
W.	NULL
Lu	NULL
,	NULL
B.	NULL
J.	NULL
Mayer	NULL
,	NULL
and	NULL
K.	NULL
Saksela	NULL
.	NULL

1998	NULL
.	NULL

SH3-domain	NULL
binding	NULL
function	NULL
of	NULL
HIV-1	NULL
Nef	NULL
is	NULL
required	NULL
for	NULL
association	NULL
with	NULL
a	NULL
PAK-related	NULL
kinase	NULL
.	NULL

Virology	NULL
250:273-282	NULL
.	NULL

Mariani	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
J.	NULL
Skowronski	NULL
.	NULL

1993	NULL
.	NULL

CD4	NULL
down-regulation	NULL
by	NULL
nef	NULL
alleles	NULL
isolated	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-infected	NULL
individuals	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:5549-5553	NULL
.	NULL

Marsh	NULL
,	NULL
J.	NULL
W.	NULL
1999	NULL
.	NULL

The	NULL
numerous	NULL
effector	NULL
functions	NULL
of	NULL
Nef	NULL
.	NULL

Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

365:192-198	NULL
.	NULL

INDUCIBLE	NULL
ACTIVATION	NULL
OF	NULL
HIV-1	NULL
Nef	NULL
FUNCTION	NULL
IN	NULL
T	NULL
CELLS	NULL
43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

843	NULL
Miller	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
M.	NULL
T.	NULL
Warmerdam	NULL
,	NULL
I	NULL
Gaston	NULL
,	NULL
W.	NULL
C.	NULL
Greene	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Feinberg	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
nef	NULL
gene	NULL
product	NULL
:	NULL
a	NULL
positive	NULL
factor	NULL
for	NULL
viral	NULL
infection	NULL
and	NULL
replication	NULL
in	NULL
primary	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:101-113	NULL
.	NULL

Nunn	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Marsh	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Nef	NULL
associates	NULL
with	NULL
a	NULL
member	NULL
of	NULL
the	NULL
p21	NULL
-activated	NULL
kinase	NULL
family	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70	NULL
:	NULL
6157-6161	NULL
.	NULL

Peter	NULL
,	NULL
F.	NULL
1998	NULL
.	NULL

HIV	NULL
nef	NULL
:	NULL
the	NULL
mother	NULL
of	NULL
all	NULL
evil	NULL
?	NULL

Immunity	NULL
9:433-437	NULL
.	NULL

Piguet	NULL
,	NULL
V.	NULL
,	NULL
F.	NULL
Gu	NULL
,	NULL
M.	NULL
Foti	NULL
,	NULL
N.	NULL
Demaurex	NULL
,	NULL
J.	NULL
Gruenberg	NULL
,	NULL
J.	NULL
L.	NULL
Carpentier	NULL
,	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

1999	NULL
.	NULL

Nef-induced	NULL
CD4	NULL
degradation	NULL
:	NULL
a	NULL
diacidic-based	NULL
motif	NULL
in	NULL
Nef	NULL
functions	NULL
as	NULL
a	NULL
lysosomal	NULL
targeting	NULL
signal	NULL
through	NULL
the	NULL
binding	NULL
of	NULL
beta-COP	NULL
in	NULL
endosomes	NULL
.	NULL

Cell	NULL
97:63-73	NULL
.	NULL

Piguet	NULL
,	NULL
V.	NULL
,	NULL
O.	NULL
Schwartz	NULL
,	NULL
S.	NULL
Le	NULL
Gall	NULL
,	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
downregulation	NULL
of	NULL
CD4	NULL
and	NULL
MHC-I	NULL
by	NULL
primate	NULL
lentiviruses	NULL
:	NULL
a	NULL
paradigm	NULL
for	NULL
the	NULL
modulation	NULL
of	NULL
cell	NULL
surface	NULL
receptors	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

168:51-63	NULL
.	NULL

Piguet	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
Nef	NULL
protein	NULL
of	NULL
primate	NULL
lentiviruses	NULL
.	NULL

Rev	NULL
.	NULL

Med	NULL
.	NULL

Virol	NULL
.	NULL

9:111-120	NULL
.	NULL

Piguet	NULL
,	NULL
V.	NULL
,	NULL
L.	NULL
Wan	NULL
,	NULL
C.	NULL
Borel	NULL
,	NULL
A.	NULL
Mang	NULL
ian	NULL
,	NULL
N.	NULL
D	NULL
ex	NULL
,	NULL
G.	NULL
Th	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

2000	NULL
.	NULL

HIV-1	NULL
Nef	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
cellular	NULL
protein	NULL
PACS-1	NULL
to	NULL
downregulate	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complexes	NULL
.	NULL

Nat	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

2	NULL
:	NULL
163-167.	NULL
.	NULL

Pritchard	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
M.	NULL
L.	NULL
Samuels	NULL
,	NULL
E.	NULL
Bosch	NULL
,	NULL
and	NULL
M.	NULL
McMahon	NULL
.	NULL

1995	NULL
.	NULL

Con	NULL
ditionally	NULL
oncogenic	NULL
forms	NULL
of	NULL
the	NULL
A-Raf	NULL
and	NULL
B-Raf	NULL
protein	NULL
kinases	NULL
display	NULL
different	NULL
biological	NULL
and	NULL
biochemical	NULL
properties	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:6430-6442	NULL
.	NULL

Ravichandran	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
M.	NULL
M.	NULL
Zhou	NULL
,	NULL
J.	NULL
C.	NULL
Pratt	NULL
,	NULL
J.	NULL
E.	NULL
Harlan	NULL
,	NULL
S.	NULL
F.	NULL
Walk	NULL
,	NULL
S.	NULL
W.	NULL
Fesik	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Burakoff	NULL
.	NULL

1997	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
requirement	NULL
for	NULL
both	NULL
phos-pholipid	NULL
and	NULL
phosphotyrosine	NULL
binding	NULL
via	NULL
the	NULL
Shc	NULL
phosphotyrosine-binding	NULL
domain	NULL
in	NULL
vivo	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:5540-5549	NULL
.	NULL

Renkema	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
A.	NULL
Manninen	NULL
,	NULL
D.	NULL
A.	NULL
Mann	NULL
,	NULL
M.	NULL
Harris	NULL
,	NULL
and	NULL
K.	NULL
Saksela	NULL
.	NULL

1999	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
Nef-associated	NULL
kinase	NULL
as	NULL
p21-activated	NULL
kinase	NULL
2	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

9:1407-1410	NULL
.	NULL

Renkema	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
and	NULL
K.	NULL
Saksela	NULL
.	NULL

2000	NULL
.	NULL

Interactions	NULL
of	NULL
HIV-1	NULL
NEF	NULL
with	NULL
cellular	NULL
signal	NULL
transducing	NULL
proteins	NULL
.	NULL

Front	NULL
.	NULL

Biosci	NULL
.	NULL

5	NULL
:	NULL
D268-D283	NULL
.	NULL

Riggs	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
H.	NULL
M.	NULL
Craig	NULL
,	NULL
M.	NULL
W.	NULL
Pandori	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Guatelli	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
dileucine-based	NULL
sorting	NULL
motif	NULL
in	NULL
HIV-1	NULL
Nef	NULL
is	NULL
not	NULL
required	NULL
for	NULL
down-regulation	NULL
of	NULL
class	NULL
I	NULL
MHC	NULL
.	NULL

Virology	NULL
258:203-207	NULL
.	NULL

Saksela	NULL
,	NULL
K.	NULL
1997	NULL
.	NULL

HIV-1	NULL
Nef	NULL
and	NULL
host	NULL
cell	NULL
protein	NULL
kinases	NULL
.	NULL

Front	NULL
.	NULL

Biosci	NULL
.	NULL

2	NULL
:	NULL
D606-D618	NULL
.	NULL

Samuel	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
D.	NULL
R.	NULL
Hodge	NULL
,	NULL
Y.	NULL
M.	NULL
Chen	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Papas	NULL
.	NULL

1991	NULL
.	NULL

Nef	NULL
proteins	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
)	NULL
and	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
are	NULL
structurally	NULL
similar	NULL
to	NULL
leucine	NULL
zipper	NULL
tran-scriptional	NULL
activation	NULL
factors	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
7:697-706	NULL
.	NULL

Sawai	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
A.	NULL
Baur	NULL
,	NULL
H.	NULL
Struble	NULL
,	NULL
B.	NULL
M.	NULL
Peterlin	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Levy	NULL
,	NULL
and	NULL
C.	NULL
Cheng-Mayer	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Nef	NULL
associates	NULL
with	NULL
a	NULL
cellular	NULL
serine	NULL
kinase	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:1539-1543	NULL
.	NULL

Sawai	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
I.	NULL
H.	NULL
Khan	NULL
,	NULL
P.	NULL
M.	NULL
Montbriand	NULL
,	NULL
B.	NULL
M.	NULL
Peterlin	NULL
,	NULL
C.	NULL
Cheng-Mayer	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Luciw	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
of	NULL
PAK	NULL
by	NULL
HIV	NULL
and	NULL
SIV	NULL
Nef	NULL
:	NULL
importance	NULL
for	NULL
AIDS	NULL
in	NULL
rhesus	NULL
macaques	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

61519-1527	NULL
.	NULL

Schrager	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Marsh	NULL
.	NULL

1999	NULL
.	NULL

HIV-1	NULL
Nef	NULL
increases	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
a	NULL
stimulus-dependent	NULL
manner	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96:8167-8172	NULL
.	NULL

Schwartz	NULL
,	NULL
O.	NULL
,	NULL
V.	NULL
Marechal	NULL
,	NULL
O.	NULL
Danos	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Heard	NULL
.	NULL

1995	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Nef	NULL
increases	NULL
the	NULL
efficiency	NULL
of	NULL
reverse	NULL
transcription	NULL
in	NULL
the	NULL
infected	NULL
cell	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4053-4059	NULL
.	NULL

Schwartz	NULL
,	NULL
O.	NULL
,	NULL
V.	NULL
Marechal	NULL
,	NULL
S.	NULL
Le	NULL
Gall	NULL
,	NULL
F.	NULL
Lemonnier	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Heard	NULL
.	NULL

1996	NULL
.	NULL

Endocytosis	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
molecules	NULL
is	NULL
induced	NULL
by	NULL
the	NULL
HIV-1	NULL
Nef	NULL
protein	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

2:338-342	NULL
.	NULL

Shugars	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
M.	NULL
S.	NULL
Smith	NULL
,	NULL
D.	NULL
H.	NULL
Glueck	NULL
,	NULL
P.	NULL
V.	NULL
Nantermet	NULL
,	NULL
F.	NULL
Seillier-Moiseiwitsch	NULL
,	NULL
and	NULL
R.	NULL
Swanstrom	NULL
.	NULL

1993	NULL
.	NULL

Analysis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
nef	NULL
gene	NULL
sequences	NULL
present	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:4639-4650	NULL
.	NULL

(	NULL
Erratum	NULL
,	NULL
68:5335	NULL
,	NULL
1994	NULL
.	NULL
)	NULL

Spina	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
T.	NULL
J.	NULL
Kwoh	NULL
,	NULL
M.	NULL
Y.	NULL
Chowers	NULL
,	NULL
J.	NULL
C.	NULL
Guatelli	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Richman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
nef	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
from	NULL
primary	NULL
quiescent	NULL
CD4	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:115-123	NULL
.	NULL

Stulnig	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
M.	NULL
Berger	NULL
,	NULL
T.	NULL
Sigmund	NULL
,	NULL
D.	NULL
Raederstorff	NULL
,	NULL
H.	NULL
Stockinger	NULL
,	NULL
and	NULL
W.	NULL
Waldhausl	NULL
.	NULL

1998	NULL
.	NULL

Polyunsaturated	NULL
fatty	NULL
acids	NULL
inhibit	NULL
T	NULL
cell	NULL
signal	NULL
trans-duction	NULL
by	NULL
modification	NULL
of	NULL
detergent-insoluble	NULL
membrane	NULL
domains	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

143:637-644	NULL
.	NULL

Wang	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
E.	NULL
Kiyokawa	NULL
,	NULL
E.	NULL
Verdin	NULL
,	NULL
and	NULL
D.	NULL
Trono	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
Nef	NULL
protein	NULL
of	NULL
HIV-1	NULL
associates	NULL
with	NULL
rafts	NULL
and	NULL
primes	NULL
T	NULL
cells	NULL
for	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
97:394-399	NULL
.	NULL

Xu	NULL
,	NULL
X.	NULL
N.	NULL
,	NULL
B.	NULL
Laffert	NULL
,	NULL
G.	NULL
R.	NULL
Screaton	NULL
,	NULL
M.	NULL
Kraft	NULL
,	NULL
D.	NULL
Wolf	NULL
,	NULL
W.	NULL
Kolanus	NULL
,	NULL
J.	NULL
Mongkolsapay	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baur	NULL
.	NULL

1999	NULL
.	NULL

Induction	NULL
of	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
HIV	NULL
involves	NULL
the	NULL
interaction	NULL
of	NULL
Nef	NULL
with	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
zeta	NULL
chain	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

189:1489-1496	NULL
.	NULL

Yu	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Felsted	NULL
.	NULL

1992	NULL
.	NULL

Effect	NULL
of	NULL
myristoylation	NULL
on	NULL
p27	NULL
nef	NULL
subcellular	NULL
distribution	NULL
and	NULL
suppression	NULL
of	NULL
HIV-LTR	NULL
transcription	NULL
.	NULL

Virology	NULL
187:46-55	NULL
.	NULL

Zhang	NULL
,	NULL
W.	NULL
,	NULL
R.	NULL
P.	NULL
Trible	NULL
,	NULL
and	NULL
L.	NULL
E.	NULL
Samelson	NULL
.	NULL

1998	NULL
.	NULL

LAT	NULL
palmitoylation	NULL
:	NULL
its	NULL
essential	NULL
role	NULL
in	NULL
membrane	NULL
microdomain	NULL
targeting	NULL
and	NULL
tyrosine	NULL
phosphory-lation	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Immunity	NULL
9:239-246	NULL
.	NULL

